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CHAPTER I
INTRODUCTION
A.

Background and rationale for this study
1. The extracellular matrix: more than a scaffold
The extracellular matrix (ECM) forms a complex microenvironment in the

extracellular space and is critical for development, tissue structure, and cellular
response. The ECM consists of a myriad of proteins, glycoproteins, and
proteoglycans that form a cross-linked scaffold that surrounds cells in all solid
organs (1). These fibrous proteins are produced by cells (i.e., fibroblasts) and,
upon secretion into the extracellular environment, crosslink together to create a
meshwork that serves as a scaffold for cells and that provides structure to tissue.
The collagen scaffold to which glycoproteins and proteoglycans adhere is the
main characteristic shared by the ECM of the basement membranes and
interstitial matrices, regardless of physiological domain (1). Physical changes to
the extracellular landscape, including changes in ECM topography, crosslinking,
and biochemistry, can affect cell migration, adhesion, and activation (2). In
addition to their role as structural compounds, these proteins can also serve as
signaling molecules. Indeed, ECM proteins are ligands of cell surface receptors,
including integrins, which bind specific ECM matrix protein domains (e.g., the
RGD motif). The ECM also contributes to cell signaling by binding soluble
1

signaling molecules including cytokines, chemokines, and growth factors to
create signaling gradients required for tissue development and migration of
inflammatory cells during acute inflammation (3).
Proteases and protease inhibitors comprise another group of proteins
critical in the extracellular space. These enzymes play an important role in the
homeostasis of the extracellular environment and contribute to ECM remodeling
in disease states (4). Proteases may enhance the deposition of proteins to the
ECM (e.g., proteases involved in the complement and coagulation cascades).
Proteases can also break down matrix components to allow for rapid changes in
the ECM organization, such as matrix metalloproteinases (MMPS), a disintegrin
and metalloproteinase with thrombospondin motifs (ADAMTS), and other serine
proteases. The effects of ECM degradation by proteases modify both the
physical and biochemical environment of the extracellular space. For example,
physical dissolution of the ECM by proteases can create space through which
cells can migrate (5). Alternatively, cleavage of ECM proteins by proteases can
alter cell-ECM interactions by exposing/removing cryptic binding sites; for
example, proteolysis of laminin-5 reveals integrin-binding sites which are critical
for cell adhesion (6). Proteases can also contribute to ECM dynamics by
modulating the activity of other enzymes (e.g., proteinase precursors (7) and
soluble mediators (e.g., IL-8, (2)). Because of the wide-reaching effects of
proteases, their activity is regulated and maintained via complex, often
redundant, mechanisms. Indeed, in addition to regulation of rates of synthesis
and secretion, extracellular proteases frequently require activation, often via
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cleavage by another protease, and conversely can be inhibited by endogenous
inhibitors such as tissue inhibitors of matrix metalloproteinases (TIMPs) (5).

2. The role of the ECM in inflammation and disease.
Tight regulation of the ECM composition is necessary for normal tissue
homeostasis, and dysregulation is often a hallmark in tissue pathology.
Therefore, the organization, composition, and orientation of the ECM are
controlled via multiple mechanisms including protein synthesis, modification,
excretion, crosslinking, and enzymatic degradation. Such tight regulation on so
many levels also permits rapid changes in the ECM that allow it to play a
dynamic and responsive role during inflammation and tissue repair.
Perturbations in the ECM during either of these physiological states can
contribute to disease initiation and development.
During an acute inflammatory response, the ECM plays a pivotal role by
serving as a structural barrier and chemokine reservoir, thereby regulating
inflammatory cell migration. Indeed, studies have shown that neutrophil
transmigration is greater through vascular areas with lower ECM concentration
(8). Additionally, ECM binding of cytokines, including IL-2, TNFα, TGFβ, and
RANTES (9-11), have been shown to regulate cell activation, adhesion, and
migration. The interaction between the ECM and cell infiltration is bidirectional as leukocytes integrate structural and biochemical signals from the ECM, they in
turn release matrix-degrading proteases (12) which alter the extracellular
composition and allow for easier cell migration.
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In the setting of chronic inflammation, dysregulation of ECM composition can
lead to pathological tissue remodeling and, if not resolved, disease states
including hepatic (13, 14) and pulmonary fibrosis (15-17), atherosclerosis (18,
19) and cancer (20, 21). Initiation of these disease states can occur via
dysregulation at the level of ECM synthesis and/or degradation, leading to
altered matrix accumulation and modification. For example hepatic fibrosis is
characterized by a robust increase in collagen Iα1 secretion by hepatic stellate
cells (HSCs) (22) combined with a concomitant increase in crosslinking and a
decrease in enzymatic degradation (23). Such dynamic changes in extracellular
composition can initiate and perpetuate disease via a variety of mechanisms
including altered tissue biomechanics (i.e. tissue stiffness) (24, 25), increased
integrin-mediated cell adhesion (26) and activation of immune cells (27).

3. Statement of goals
The role of tissue remodeling in advanced stages of liver disease, including
fibrosis, is clear. Indeed, the major macroscopic change in hepatic fibrogenesis
is characterized by severe collagen deposition and scarring. Currently, hepatic
fibrosis is generally considered irreversible, and there is currently no FDAapproved therapy to halt or reverse liver fibrosis. Recent studies have shown
that transitional tissue remodeling may occur during inflammatory liver disease,
before the development of fibrosis (28). Additionally, protecting against these
subtle changes can protect against liver injury and inflammation (29). These
findings suggest that targeting the ECM in earlier stages of liver disease could
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provide therapeutic benefit by preventing disease progression to later,
irreversible stages of fibrosis. The goal of this dissertation is to examine the role
of transitional tissue remodeling in fatty liver disease. Furthermore, it aims to
identify new extracellular matrix proteins that play a role in early stages of
remodeling which could serve as novel therapeutic targets.

4. Natural history of liver disease
The natural history of liver disease is well documented and encompasses a
spectrum of disease states including earlier stages of fatty liver disease such as
steatosis, steatohepatitis, and later stages of disease including fibrosis and
cirrhosis (30, 31). The earliest stage of liver disease, simple steatosis, is
characterized by micro- and macro-vesicular fat accumulation and is generally
considered reversible if appropriate changes to the lifestyle are made and
maintained. In the absence of lifestyle modifications, individuals may develop
steatohepatitis, which is characterized by persistence of accumulated fat in
addition to chronic hepatic inflammation (hepatitis). Later stages of liver disease,
including fibrosis and cirrhosis, are characterized by collagen deposition and
regenerative nodules, respectively (31, 32).
Despite the vast amount of money spent on treating alcoholic liver disease,
therapeutic options remain limited to palliative care in the late stages of disease.
Currently there is no FDA-approved therapy in existence to halt or reverse
disease progression. If a rational, targeted therapy is to be developed, currently
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accepted mechanisms of disease progression must be better understood and
new therapeutic targets identified.

5. Alcoholic liver disease
Alcohol is one of the most commonly recognized causes of liver disease.
Alcoholic liver disease (ALD) affects more than 10 million Americans each year
at a cost of more than $166 billion annually to treat the medical consequences of
this disease (33). After absorption from the small intestine, milli-molar
concentrations of ethanol flow through the portal circulation and to the liver for
degradation making the liver a prime target of ethanol toxicity. During oxidative
metabolism of alcohol in hepatocytes by alcohol dehydrogenase (ADH) and
CYP2E1, a robust increase in the NADH/NAD+ ratio lends to a more reduced
cellular environment. This reduced microenvironment blocks the beta-oxidation
of fatty acids in the liver and increases the esterification of fatty acids.
Accumulation of excess fatty acids in the liver leads to storage of these lipids in
lipid droplets known as steatosis, which is a hallmark of early liver disease.
Steatosis develops in nearly all individuals who consume moderate
amounts of alcohol, and for most people has no health consequences. Indeed,
at the organismal level, hepatic steatosis may be viewed as a protective
mechanism, as it restricts plasma lipid levels from rising. However chronic
alcohol consumption can lead to development of later stages of liver disease,
including alcoholic steatohepatitis (ASH) as well as fibrosis and cirrhosis. These
more severe stages of ALD develop in only a minority of chronic alcoholics. One
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explanation for this discrepancy is the 2-hit hypothesis, which suggests that
progression from simple steatosis to later stages of liver disease requires
multiple insults, or ‘hits’ (34, 35). According to this paradigm, a first ‘hit,’ such as
hepatic steatosis, sensitizes the liver to a second hit such as oxidative stress (36)
or inflammatory cytokine signaling (37), both of which are also increased by
ethanol consumption.

6. Non-alcoholic fatty liver disease (NAFLD)
Another common cause of fatty liver disease is obesity. Obesity is a growing
problem both nationally and globally, with statistics estimated that more than 78
million U.S adults are clinically obese (38). Obesity is associated with a myriad
of health effects including metabolic syndrome, cardiovascular risks, and nonalcoholic fatty liver disease (NAFLD). It has been difficult to estimate the
prevalence of NAFLD within populations and figures range depending on the
cohort studied, however current estimates indicate that up to 19% of the
American population may have some degree of NAFLD (39), with the highest
prevalence of NAFLD among the morbidly obese (40). Interestingly, despite a
high prevalence of steatosis among obese individuals, it is estimated that less
one third of patients with NAFLD will develop nonalcoholic steatohepatitis
(NASH) (40-42), the more severe inflammatory stage of the disease. Increased
susceptibility to disease progression in some individuals is likely due to a variety
of factors, including genetic predisposition, and environmental exposures (43).
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Similar to ALD, it is hypothesized that multiple hits are required for the
development of later stages of NAFLD (34, 43).
Our lab is particularly interested in the enhanced susceptibility to liver injury
caused by low levels of arsenic in the setting of NAFLD. Arsenic is a natural
contaminant of the drinking water and at very high concentrations has been
shown to cause overt liver damage (44, 45). Arsenic levels found in the United
States are generally considered too low to cause toxicity, however even low
levels of arsenic exposure have been linked to subtle hepatic changes including
capillarization of sinusoidal endothelial cells, a type of remodeling response in
the liver (46). Moreover, low levels of arsenic have also been shown to sensitize
the liver to inflammatory insult (47). A previous study from our group has
implicated an interaction between HFD and subhepatotoxic arsenic exposure, the
combination of which caused enhanced liver injury. These data support the
hypothesis that HFD may sensitize the liver to otherwise innocuous toxins,
including arsenic, resulting in progression of liver disease. As will be
demonstrated in this work, a key effect of arsenic appears to be to enhance the
deposition of fibrin ECM in response to HFD.

7. ECM in fatty liver disease
As mentioned above, the major part of the study of the role of the ECM in liver
disease has focused on the robust increase in collagen deposition which is a
hallmark of hepatic fibrosis. However, other studies have shown that other ECM
components, including fibronectin, elastin, laminin and hyaluron, are also altered
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during hepatic fibrogenesis (48). Global changes in the distribution and
concentration of many different ECM components likely contribute to pathological
tissue remodeling and the progression of fibrogenesis.
Recent studies suggest that transitional tissue remodeling may occur before
fibrosis. For example, Gillis et al showed that ethanol exposure increases the
secretion of fibronectin, a structural component of the ECM, by hepatic stellate
cells (HSCs) prior to their activation (28). Since activated HSCs play a role in
fibrogenesis, these results suggesting that fibronectin secretion is increased prior
to fibrogenesis. This group has also shown that enhanced LPS-induced fibrin
accumulation caused by acute alcohol exposure is critical to liver injury and
inflammation (29, 49, 50). It is likely that there are changes in other ECM
proteins contributing to hepatic inflammation. In support of this possibility, a
proteomic approach used by Lai et al showed that a myriad of ECM-associated
proteins are dysregulated during hepatocarcinogenesis (51) Applying this
proteomics technique to changes in the hepatic ECM proteome could identify
potential players in transitional tissue remodeling in early stages of fatty liver
disease.

8. Alcoholic lung phenotype
It has been estimated that up to 190,000 people suffer from acute lung injury
(ALI) annually in the United States (52). The risk of developing more severe
forms of ALI such as acute respiratory distress syndrome (ARDS), is significantly
higher in chronic alcoholics (53). Furthermore, a history of chronic alcohol
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consumption has been shown to increase the risk of mortality in ARDS patients
(54). Subsequent rodent studies investigating the possible mechanisms
underlying the detrimental effects of alcohol on the lung indicate that chronic
alcohol may cause a myriad of pulmonary changes, coined the ‘alcoholic lung
phenotype,’ including increased pro-inflammatory cytokine release (54-57),
induction of oxidative stress (58), and tissue remodeling (59, 60). The
dysregulated inflammatory response caused by alcohol is dependent on both the
amount and duration of alcohol consumption and is suspected to be a key player
in alcohol-related lung dysfunction (61). The exact mechanisms that result in the
‘alcoholic lung phenotype’ remain unclear, but, if identified, would point to
potential targets for intervention in alcohol-related lung dysfunction.

9. Parallel mechanisms of injury in the liver and lung
Currently, the effects of chronic ethanol exposure on the liver and lung are
considered to be independent of each other and thus are often studied
separately. However, independent studies investigating the effects of ethanol on
the liver and lung individually have revealed that similar mechanisms are at play
in each organ and, more specifically, that these organs have similar responses to
alcohol exposure. For example, alcohol enhances LPS-induced organ damage
in both the liver and lung (58, 62). Additionally, oxidative stress, a well-known
mediator of alcohol-induced liver injury (63) is also involved in increased
susceptibility to lung injury caused by alcohol (64). Furthermore, both organs
possess resident macrophages that can play a critical role in dysregulated
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inflammation after alcohol exposure (65) and both exhibit subtle changes in the
composition of the extracellular matrix (ECM) following alcohol exposure. The
deleterious effects of tissue remodeling are well understood with regards to
hepatic (66) and pulmonary fibrosis (67), however recent work from both this lab
and Roman’s group have implicated more subtle ECM changes to be a key step
in disease progression in the liver and lung, respectively. Specifically, the
Roman lab has shown that chronic alcohol exposure increases pulmonary
fibronectin deposition via alterations in both expression and degradation of ECM
components (68). Similarly, our lab has shown that ethanol enhances increased
hepatic fibrin deposition caused by LPS and that subsequent inflammatory
damage to the liver is a direct effect of fibrin accumulation (29, 50, 69-71).

10. The gut-liver-lung axis
Chronic alcohol abuse can act as a first ‘hit’ that leads to alterations in tissue
architecture without causing detectible organ damage. This alcoholic first ‘hit’
can render the host susceptible to injury in the presence of a second stimulus,
such as endotoxemia. Circulating levels of endotoxin (i.e. LPS) are increased in
chronic alcoholics due to changes in intestinal permeability caused by alcohol
exposure. This increase in circulating endotoxin appears to be a common
second ‘hit’ that drives progression of liver and lung injury. While the role of the
gut:liver axis in alcohol induced liver disease is now well-established (72, 73), we
propose that organ-organ interactions after alcohol exposure are not limited to
the gut:liver axis but may also include the lung. For example, more than 30
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years ago one cohort study showed that end-stage liver disease increased
mortality associated with ARDS from 40-60% to 100% (74), suggesting that liver
injury may directly impact susceptibility to lung injury. Other studies investigating
the multi-organ effects of endotoxemia indicate that interaction between the liver
and lung is not only likely, but may occur via LPS-induced mediators (75)
including TNFα (76), an inflammatory cytokine markedly increased in both endstage liver patients (77) and experimental models of liver injury. The role of
TNFα in pulmonary injury is also well established (55). As mentioned above, the
effects of chronic ethanol exposure on the liver and lung have most often been
studied independently. In order to study the possibility of interdependence
between these two organs, a model of concomitant liver and lung injury must be
established. Once established, additional studies investigating possible links
between liver and lung injury will allow a better understanding of inter-organ
interactions in this model.
B. Aims and proposals
1. Protective effects of prebiotics in the setting of non-alcoholic liver
disease
Our lab has already shown that arsenic can sensitize the liver to non-alcoholic
fatty liver disease caused by a high fat diet. In this model, enhanced damage
correlated with an increase in hepatic inflammation and in sinusoidal fibrin
deposition in the liver. Hepatic inflammation and injury caused by a HFD is
mediated by multiple mechanisms, including gut dysbiosis. Indeed, HFD feeding
increases gut leakiness, causing endotoxemia and systemic inflammation (78)
12

and liver steatosis (79). Protecting against endotoxemia by altering the
microbiota caused by HFD exposure can also protect against inflammation and
metabolic syndrome in mice (80). Furthermore, the benefits of pre- and
probiotics on liver injury have been established in models of alcoholic and nonalcoholic liver disease (81-83). Enhanced liver injury caused by the combination
of HFD and arsenic in this model may be mediated by interactions between HFD
and arsenic on the gut microbiome. Therefore the goals of this study were to 1)
determine the protective effects of oligofructose (OFC) and 2) to identify
interactions between HFD, arsenic, and OFC on the gut microbiome in a model
of enhanced liver injury caused by concomitant exposure to HFD and arsenic.
Importantly, fibrin ECM deposition may play a key role in this response.

2. Characterization of a model of concomitant liver and lung injury
A number of studies independently investigating the liver and lung response
to chronic alcohol exposure have indicated that similar mechanisms contribute to
alcohol-induced changes in these two organs including oxidative stress,
dysregulated inflammatory response, and tissue remodeling. An important
function of the liver is as a host-defense system; thus liver injury and the
resultant reduction in hepatic function could enhance susceptibility of other
organs to injury, including the lungs. For example, mortality due to ARDS was
increased to nearly 100% in individuals with end-stage liver disease (74). This
as well as work by Siore et al (84) have indirectly suggested that liver injury
and/or hepatic-derived mediators may drive injury in the lung. One potential link
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between liver and lung injury is the pro-inflammatory cytokine TNFα. TNFα
levels in the systemic circulation are increased after alcohol exposure in both
experimental models of alcohol exposure (85, 86) and in patients with ALD (77).
The resident hepatic macrophages, Kupffer cells, are known to be a major
source of pro-inflammatory mediators into the systemic blood (65, 87) and likely
contribute to the robust increase in pro-inflammatory signaling after alcohol
exposure. Moreover, TNFα has also been linked to pulmonary injury in
experimental models (88, 89). Therefore, the purpose of this study was to
characterize a model of concomitant liver and lung injury and to investigate the
potential role of TNFα as link between liver and lung injury after chronic alcohol
exposure. These studies lay the groundwork for future studies on the interaction
of the role of the liver in lung ECM remodeling in the ‘alcoholic lung phenotype.’
3. Can we characterize the hepatic extracellular proteome?
As mentioned above, the role of the ECM in later stages of liver disease (i.e.,
fibrosis) is well recognized. Previous studies from this lab and other groups (28,
90) have shown that changes in the ECM also occur in early pre-fibrotic stages of
liver disease. These transitional changes in the ECM appear to play a critical
role in the sensitization of the liver to insult, particularly in the context of fatty
liver. While several matrix proteins have been implicated as players in liver injury
and inflammation (i.e., fibrin, fibronectin) there are likely other ECM proteins that
also contribute to hepatic injury. Identification of new ECM proteins that are
altered by ethanol exposure would provide new insights into mechanisms of
hepatic tissue remodeling that contribute to progression of ALD. There are likely
14

changes in the hepatic ECM that have not yet been identified due to the
insolubility of matrix proteins making them difficult to extract and analyze.
Additionally, the study of alterations to the hepatic ECM has primarily been
hypothesis-driven which can hamper the discovery of new potential players. The
purpose of this study was to use a serial extraction technique which would allow
extraction and enrichment of tightly cross-linked proteins coupled with LC-MS
analysis. When paired together, these methods will allow extraction of proteins
with low expression levels and poor solubility and analysis of global changes in
the hepatic ECM.

Overall aim of this dissertation.
The overall aim of this dissertation is to build on the unifying hypothesis that
ECM dyshomeostasis contributes to hepatic pathology, as well as to pathology in
other organs, such as the lung. Indeed, as described above, the enhancement of
liver injury caused by arsenic exposure in the context of HFD (Aim 1) is
characterized by a robust increase in fibrin deposition; the intervention strategies
that protect against this pathology will shed new insight into future studies. The
development of a new model to characterize the interaction between liver and
lung in the alcoholic lung phenotype (Aim 2), coupled with the new ECM
proteomic strategies (Aim 3), lay the foundation for testing the hypothesis that
liver injury is critical in transitional ECM remodeling that occurs with alcohol
exposure (i.e., the ‘alcoholic lung phenotype’). Taken together, this work will

15

shed new mechanistic insight into the complex interplay between injury, matrix
dyshomeostasis and disease progression.
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CHAPTER II
EXPERIMENTAL PROCEDURES

A. Animals and treatments
Mice were housed in a pathogen-free barrier facility accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care, and
procedures were approved by the University of Louisville’s Institutional Animal
Care and Use Committee.
At time of sacrifice, animals were anesthetized with ketamine/xylazine
(100/15 mg/kg, i.p.). Blood was collected from the vena cava just prior to
sacrifice by exsanguination and citrated plasma was stored for further analysis.
Prior to lavage of the lungs, 10 mL of PBS was perfused through the heart to
flush the pulmonary vasculature of erythrocytes. Bronchioalveolar lavage (BAL)
was performed by flushing the lung two times with 400 μL sterile PBS. Cells in
the BAL fluid (BALF) were separated by centrifugation and removed from
remaining BALF and fixed on slides for further analysis (91). Portions of liver
tissue and lung tissue were snap-frozen in liquid nitrogen for later analysis or
fixed in 10% neutral buffered formalin for subsequent sectioning and mounting on
microscope slides. A portion of liver tissue was frozen-fixed in Tissue Tek OCTCompound (Satura Finetek, Torrance, CA). Total RNA was immediately
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extracted from fresh liver and lung tissue using RNA-stat (Tel-Test, Austin, TX)
and chloroform: phenol separation (see RNA isolation Methods).
1. Arsenic, high fat diet, and oligofructose feeding
Four week old male C57Bl6/J mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). Food and tap water were allowed ad libitum. Mice
were fed AIN-76 Purified diet (Harlan Laboratories) for one week to reduce
potential confounding factors of arsenic present in standard laboratory chow (92).
Mice were exposed to sodium arsenite (4.9 ppm in drinking water) or tap water
for one week prior to initiating feeding with either commercially available
experimental diets (Table 2.1; Harlan Laboratories, Madison WI) including a low
fat diet (LFD; 13% fat in calories), a high fat diet (HFD; 42% fat in calories), or a
HFD containing the prebiotic oligofructose (5% w/w OFC) for 10 weeks. This
exposure level of arsenic was determined by preliminary range-finding
experiments to cause no overt liver damage in mice fed low-fat diet. Food and
water consumption were measured twice a week. Body weight was measured
once a week
2. Chronic model of alcohol exposure
Eight week old male C57BL6/J mice were purchased from the Jackson
Laboratory (Bar Harbor, ME) and exposed to either ethanol-containing LieberDeCarli diet (Dyets, Inc.) or iso-caloric control diet. During the exposure period,
animals were housed in pairs in shoebox cages in a room held at 75 ⁰F. Diet
was provided in vacuum tubes and replaced between 4 and 5 pm daily. Both
ethanol-fed animals and their pair-fed counterparts received control diet for the
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Table 2.1. Diet Composition
Low Fat Diet
% kCal
Source
(% by weight)

High Fat Diet
% kCal
Source
(% by weight)

Protein

19.2

Casein

15.2

Casein

Carbohydrate

67.9

Sucrose/Corn
starch

42.7

Sucrose/Corn
starch

Fat

13.0

Milkfat (3.7%)/
soybean oil (1.3%)

42.0

Milkfat (21.2%)

kCal/g

3.6

4.5
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first two days of liquid diet feeding to allow acclimation to the liquid diet feeders.
After 2 days of acclimation, ethanol concentrations increased incrementally over
the course of three weeks before reaching the highest ethanol concentration, 6%
(vol/vol) for the final three weeks of exposure. Ethanol concentrations in the
ethanol-containing diets were as follows: 0% for two days of acclimation, 1% for
two days, 2% for two days, 4% for one week, 5% for one week, and 6% for three
weeks. Ethanol-containing diet was provided ad libitum for the entire course of
the study. Because of the relatively high caloric content of ethanol, pair-fed
control animals received an iso-caloric control diet; the calories in the iso-caloric
diet were matched by adding a calorie-equivalent of maltose-dextrin. To account
for the reduced food consumption of ethanol-fed mice, pair-fed mice were given
the volume of diet consumed by their ethanol-fed counterparts the night before.
At the conclusion of the feeding period, the two diet groups were further
separated into additional groups that received either LPS (E. coli; 10 mg/kg i.p
Sigma, St. Louis, MO) or vehicle (saline). Animals were euthanized 4 or 24 h
after LPS (or vehicle) injection.
a. Etanercept administration
Etanercept (Etan; Wyeth) is an FDA-approved TNFα blocker. Etanercept
is a fusion protein of the human p75 TNF receptor attached to the Fc portion of
human IgG1. In this study, some animals were administered etanercept (10
mg/kg in PBS) by i.p. injection two times per week during ethanol administration,
as described by others (93, 94). Control animals received PBS vehicle, (1 μl/g;
i.p) twice per week.
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B. Proteomics
1. 3-step ECM extraction (95-97)
Sample preparation and wash. Snap frozen liver tissue (75-100 mg) was
immediately added to ice-cold phosphate-buffered saline (pH 7.4) wash buffer
containing commercially available protease and phosphatase inhibitors (Sigma
Aldrich) and 25 mM EDTA to inhibit proteinase and metalloproteinase activity,
respectively. While immersed in wash buffer, liver tissue was diced into small
fragments using a scalpel. The diced sample was washed 5 times to remove
contaminants. Between washes, samples were pelleted by centrifugation at
10,000×g for 5 min and wash buffer was decanted. NaCl extraction. Diced
samples were incubated in 10 volumes of 0.5 M NaCl buffer, containing 10 mM
Tris HCl (pH 7.5), proteinase/phosphatase inhibitors, and 25 mM EDTA. The
samples were mildly mixed on a plate shaker (800 rpm) overnight at room
temperature. The following day, the remaining tissue pieces were pelleted by
centrifugation at 10,000×g for 10 min. The supernatant was saved and labeled
as the NaCl fraction. SDS extraction. The pellet from the NaCl extraction was
subsequently incubated in 10 volumes (based on original weight) of a 1% SDS
solution, containing proteinase/phosphatase inhibitors and 25 mM EDTA. The
samples were mildly mixed on a plate shaker (800 rpm) overnight at room
temperature. The following day, the remaining tissue pieces were pelleted by
centrifugation at 10,000×g for 10 min. The supernatant was saved and labeled
as the SDS extract. Guanidine HCl extraction. The pellet from the SDS
extraction was incubated with 5 volumes (based on original weight) of a
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denaturing guanidine buffer containing 4 M guanidine HCl (pH 5.8), 50 mM
sodium acetate, 25 mM EDTA, and proteinase/phosphatase inhibitors. The
samples were vigorously mixed on a plate shaker at 1200 rpm for 48 hours at
room temperature; vigorous shaking is necessary at this step to aid in the
mechanical disruption of ECM components. The remaining insoluble
components were pelleted by centrifugation at 10,000×g for 10 minutes. This
insoluble pellet was retained and solubilized as described below. The
supernatant was saved and labeled as the GnHCl fraction. Deglycosylation and
solubilization. The supernatants from each extraction were desalted using
ZebaSpin columns (Pierce) according to manufacturer’s instructions. The
desalted extracts were then mixed with 5 volumes of 100% acetone and stored at
-20⁰C overnight to precipitate proteins. The precipitated proteins were pelleted
by centrifugation at 16,000×g for 45 minutes. Acetone was evaporated by
vacuum drying in a RotoVap for 1 hour. Dried protein pellets were resuspended
in 500 uL deglycosylation buffer (150 mM NaCl, 50 mM sodium acetate, pH 6.8,
10 mM EDTA, and proteinase/phosphatase inhibitors) that contained
chondroitinase ABC (P. vulgaris; 0.025 U/sample), endo-beta-galactosidase (B.
fragilis; 0.01 U/sample) and heparitinase II (F. heparinum; 0.025 U/sample).
Samples were incubated overnight at 37⁰C. Samples containing the pellet
remaining after the guanidine HCl step received 20 uL DMSO to aide in
solubilization. Protein concentrations were estimated by absorbance at 280 nm
using BSA in deglycosylation buffer for reference standards.
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2. Sample cleanup and preparation for liquid chromatography
Pooled samples in deglycosylation buffer were provided to and
subsequently analyzed by the University of Louisville Proteomics Biomarkers
Discovery Core (PBDC). At the PBDC, samples in deglycosylation buffer were
thawed to room temperature and clarified by centrifugation at 5,000xg at 4°C for
5 min. Samples were reduced by adding 5.55 µL of 1 M DTT to 50 µL (25 µg) of
each sample and then incubating at 60°C for 30 min after which 144.45 µL of 8 M
urea in 0.1 M Tris-HCl pH 8.5 was added to each sample. Each reduced and
diluted sample was digested with a modified Filter-Aided Sample Preparation
(FASP) method. Recovered material was dried in a SpeedVac and redissolved
in 200 μL of 2% (v/v) acetonitrile (ACN)/0.4% formic acid (FA). The samples
were then trap-cleaned with a C18 PROTOTM 300Å Ultra MicroSpin Column (The
Nest Group, Southborough, MA). The sample eluates were stored at -80°C for
30 min, dried in a SpeedVac, and stored at -80°C until analysis. Before liquid
chromatography, dried samples were warmed to room temperature and
dissolved in 2% (v/v) ACN/0.1% FA to a final concentration of 0.25 μg/μL. For
analysis 16 μL (4 μg) of sample was injected into the Orbitrap Elite.
3. Liquid Chromatography
Dionex Acclaim PepMap 100 75 μm x 2 cm nanoViper (C18, 3 µm, 100 Å)
trap and Dionex Acclaim PepMap RSLC 50 μM x 15 cm nanoViper (C18, 2 µm,
100 Å) separating columns were used. An EASY n-LC (Thermo, Waltham, MA)
UHPLC system was used with buffer A = 2% (v/v) acetonitrile / 0.1% (v/v) formic
acid and buffer B = 80% (v/v) acetonitrile / 0.1% (v/v) formic acid as mobile
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phases. Following injection of the sample onto the trap, separation was
accomplished with a 140 min linear gradient from 0% B to 50% B, followed by a
30 min linear gradient from 50% B to 95% B, and lastly a 10 min wash with 95%
B. A 40 mm stainless steel emitter (Thermo, Waltham, MA; P/N ES542) was
coupled to the outlet of the separating column. A Nanospray Flex source
(Thermo, Waltham, MA) was used to position the end of the emitter near the ion
transfer capillary of the mass spectrometer. The ion transfer capillary
temperature of the mass spectrometer was set at 225°C, and the spray voltage
was set at 1.6 kV.
4. Mass Spectroscopy
An Orbitrap Elite – ETD mass spectrometer (Thermo) was used to collect
data from the LC eluate. An Nth Order Double Play with ETD Decision Tree
method was created in Xcalibur v2.2. Scan event one of the method obtained an
FTMS MS1 scan for the range 300-2000 m/z. Scan event two obtained ITMS
MS2 scans on up to ten peaks that had a minimum signal threshold of 10,000
counts from scan event one. A decision tree was used to determine whether
collision induced dissociation (CID) or electron transfer dissociation (ETD)
activation was used. An ETD scan was triggered if any of the following held: an
ion had charge state 3 and m/z less than 650, an ion had charge state 4 and m/z
less than 900, an ion had charge state 5 and m/z less than 950, or an ion had
charge state greater than 5; a CID scan was triggered in all other cases. The
lock mass option was enabled (0% lock mass abundance) using the 371.101236
m/z polysiloxane peak as an internal calibrant.
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5. Data Analysis
Proteome Discoverer v1.4.0.288 was used to analyze the data collected by
the mass spectrometer. The database used in Mascot v2.4 and SequestHT
searches was the 6/2/2014 version of the UniprotKB Mus musculus reference
proteome canonical and isoform sequences. In order to estimate the false
discovery rate, a Target Decoy PSM Validator node was included in the
Proteome Discoverer workflow.
The Proteome Discoverer analysis workflow allows for extraction of MS2
scan data from the Xcalibur RAW file, separate searches of CID and ETD MS2
scans in Mascot and Sequest, and collection of the results into a single file (.msf
extension). The resulting .msf files from Proteome Discoverer were loaded into
Scaffold Q+S v4.3.2. Scaffold was used to calculate the false discovery rate
using the Peptide and Protein Prophet algorithms. The results were annotated
with mouse gene ontology information from the Gene Ontology Annotations
Database
C. Clinical chemistry
Levels of alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were determined spectrophotometrically using standard kits (Thermotrace,
Melbourne, Australia).
D. Hepatic lipid measurements
Total lipid was extracted from mouse livers as previously described (98, 99).
Briefly, mouse liver (25-50 mg) was pulverized in a liquid-nitrogen cooled mortar
and pestle. Pulverized liver tissue was incubated in a methanol:chloroform (2:1)
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mixture on ice for thirty minutes. At the end of incubation, extracts were
centrifuged at 900 x g for 10 min at 15⁰C. After centrifugation, lipids are
partitioned into the chloroform (bottom) layer. This bottom layer was removed
using a glass syringe and dried in an evaporating centrifuge. The resulting pellet
was resuspended 5% fatty acid-free bovine serum albumin then frozen at -80⁰C
overnight. Prior to analysis, samples were vortexed then sonicated for 10
minutes at 37⁰C in a bath sonicator. Hepatic triglyceride (Thermo Scientific,
Middletown, VA) non-esterified fatty acids (Sigma Aldrich, St. Louis MO) were
determined using standard kits. Values were normalized to initial liver tissue
weight.
E. Histology
1. General morphology
Formalin fixed, paraffin embedded liver and lung tissue were cut at 5 μm and
mounted on charged glass slides. Sections were deparaffinized with Citrisolv
(Fisher, Waltham, MA) and rehydrated through graded ethanol. Sections were
then stained with hematoxylin and eosin (H&E). After staining, samples were
dehydrated through graded alcohol, washed in Citrisolv and then mounted with
Permount (Fisher, Waltham, MA).
2. Neutrophil accumulation
Chloroacetate esterase (CAE) staining for neutrophils was performed using
the naphthol AS-D chloroacetate esterase kit (Sigma, St. Louis, MO) on paraffin
embedded sections (5 μm). For blinded quantitation, samples were de-identified
and 10 fields were photographed at 400x magnification and saved. For liver
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tissue, the extent of CAE staining was quantified by counting the number of CAEpositive neutrophils per 1000 hepatocytes (69). For lung tissue, total CAEpositive cells were counted per 10 fields. During quantification, neutrophils were
characterized by light pink (i.e. CAE-positive) staining and bi-lobed nuclear
morphology.
3. Immunohistochemistry
Immunohistochemical staining for the marker F4/80 was performed as
previously described (98). Formalin-fixed, paraffin embedded sections (5 μm)
were deparaffinized and rehydrated with graded ethanol solutions. Endogenous
peroxidase activity was quenched by incubating slides in a 3% H2O2 solution for
5 minutes at room temperature. Because the liver has high concentrations of
biotin, an avidin-biotin blocking reagent (Dako, Carpinteria, CA) was used to
reduce non-specific staining. Slides were then incubated in primary antibody for
the F4/80 cell surface receptor (1:500 in 10% goat serum; Abcam, Cambridge
MA) for two hours at room temperature. The Vectastain Elite ABC kit was used
for detection (Vector Laboratories, Inc., Burlingame, CA). Briefly, tissue was
incubated in a biotinylated anti-Rat IgG secondary antibody for 15 minutes at
room temperature. Tissue was then washed and incubated in a solution
containing avidin-bound horseradish peroxidase (HRP) for 30 minutes. The HRP
substrate 3, 3’-diaminobenzidine (DAB) was added to tissue sections until
positive (brown) staining was macroscopically visible. Slides were
counterstained with Hematoxylin (Dako, Carpinteria, CA) for 1 minute, washed,
dehydrated through graded ethanol and then mounted with Permount (Fisher,
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Waltham, MA). Each slide contained a negative tissue section which does not
receive primary antibody. The number of F4/80 macrophages in liver tissue was
quantified by blinded counting of the number of F4/80 positive macrophages per
1000 hepatocytes in 200x photomicrographs.
4. Immunofluorescence
Immunofluorescent detection of fibrin deposition was performed as described
in (69). Briefly, frozen liver sections (6 μm thick) were fixed in 10% buffered
formalin containing 2% acetic acid to solubilize all but cross-linked fibrin.
Sections were blocked with PBS containing 10% horse serum before an
overnight incubation at 4⁰C with affinity purified rabbit anti-human fibrinogen IgG
(Dako North America, Inc. Carpinteria, CA) diluted in blocking solution. Donkey
anti-rabbit antibody conjugated to Alexa 488 (Invitrogen, Carlsbad, CA) was used
as secondary antibody. Tissue was counterstained with Hoechst. Fluorescence
for Alexa 488 and Hoechst was detected at excitation and emission wavelengths
of 490 nm and 520 nm, and 350 nm and 460 nm, respectively.
Immunofluorescence was visualized using a Nikon Eclipse E600 microscope
(Nikon Corporation, Tokyo, Japan) and Metamorph software
F. RNA isolation and real-time RT-PCR
The hepatic mRNA expression of select genes was detected by quantitative
reverse-transcriptase polymerase chain reaction (RT-PCR), which is routine for
this group (29, 50, 98, 100). PCR primers and probes for TNFα, PAI-1, IL-6, and
β-actin were designed using Primer 3 (Whitehead Institute for Biomedical
Research, Cambridge, MA). Primers and probes for KC, MIP-2, and IL-10 were
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bought from Applied Biosystems as kits (Foster City, CA). All primers were
designed to cross introns to ensure that only cDNA and not genomic DNA was
amplified.

Total RNA was extracted from liver tissue by a guanidinium

thiocyanate-based method (RNA STAT 60 Tel-Test, Ambion, Austin, TX). RNA
concentrations were determined spectrophotometrically and 1 μg of total RNA
was reverse transcribed using a kit (Quanta Biosciences, Gaithersburg, MD).
PerfeCta qPCR Fast Mix (Quanta Biosciences, Gaithersburg, MD) was used to
prepare the PCR reaction mixture. This 2× mixture is optimized for TaqMan
reactions and contains MgCl2, dNTPs, and AccuFast Taq DNA Polymerase.
Amplification reactions were carried out using the ABI StepOne Plus machine
and software (Life Technologies, Grand Island, NY) with initial holding stage
(95⁰C for 30 seconds) and 50 cycles of a 2-step PCR (95⁰C for 30 seconds,
60⁰C for 20 seconds).

Fluorescent intensity of each sample was measured at

each cycle to monitor amplification of the target gene. The comparative CT
method was used to determine fold changes in mRNA expression compared to
an endogenous reference gene (β-actin). This method determines the amount of
target gene, normalized to an endogenous reference and relative to a calibrator
(2-ΔΔCt).
G. Luminex
Cytokine levels in plasma and BALF samples were measured using the
MILLIPLEX MAP Magnetic Bead Mouse Cytokine/Chemokine Panel (Millipore,
Billerica, MA). The plate was read using a Luminex 100 plate reader and
Exponent software. MILLIPLEX MAP assay was performed according to
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manufacturer’s recommendations. Plasma (4x dilution) or BALF samples
(undiluted) were added to a clear bottomed black 96 well plate. Antibodyimmobilized beads were added to samples and the plate was incubated
overnight at 4⁰C on a plate shaker at 600 rpm. Detection antibody was added to
wells and incubated for 1 hour followed by the addition of strepavidinphycoerythrin. Quantitative analysis of the assay was performed using the
Luminex 100TM IS. Data capture and analysis were performed using the Luminex
Xponent software.
H. Microbiota analysis
1. Bacterial DNA isolation and sequencing
DNA was extracted from frozen cecal pellet and plasma using the QIAamp
DNA Stool Mini Kit (Qiagen) according to the manufacturer’s directions.
Briefly, cecal content (75-100 mg) was rapidly weighed, recorded, and placed
into a 2 mL microcentrifuge tube on ice. Lysis buffer was added to each
sample and the sample was vortexed until thoroughly homogenized.
Homogenized sample was heated at 70⁰C for 5 minutes and then vortexed at
full speed for 1 minute to pellet particles. Supernatant was removed and
added to a new tube with an InhibitEX tablet (supplied by kit) which forms a
matrix to pellet DNA-degrading enzymes. Samples were centrifuged to pellet
inhibitors bound to the matrix; remaining supernatant was added to a new
tube and incubated with proteinase K. DNA was then precipitated with
ethanol and collected using the QIAmp spin column as directed by
manufacturer’s instructions.
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100 ng of cecal DNA was sent to Baylor University School of Medicine’s
Alkek Center for Metagenomics and Microbiome Research for 16S rRNA
sequencing on the 454 FLX-titanium Platform. The V3–V5 16S rRNA gene
variable regions were amplified by PCR using 454 adapter-linked and barcoded primers 357F and 926R, as described previously (101). Negative
controls (water) and positive controls (Staphylococcus aureus USA300
genomic DNA) were included in all steps to control for contamination.
Amplicons were purified using a SPRI bead clean-up step, quantitated by
picogreen assay, normalized, pooled, and then sequenced on a 454
instrument using the FLX Titanium chemistry.
2. Bacterial DNA analysis
The raw sequencing dataset, consisting of an average of 28,590 reads per
sample with an average read length of 253 nucleotides, was deconvoluted
via the PyNAST alignment tool (102) using the Greengenes reference
database (August 2013 release) (103) and quality filtered with cutoff
parameters of: less than 200 and greater than 1,000 bp, quality score below
30, number of mismatches in primer greater than 0, number of ambiguous
bases greater than 6, and maximum homopolymer runs greater than 6.
Following quality filtering, 514,622 sequences remained from the original
531,138 with an average read length of 253 nucleotides. Chimeric
sequences were removed by reference and de novo chimeric filtering with
UCHIME (104) utilizing the Greengenes reference database (August 2013
release) (103). Operational taxonomic unit tables based on sequences
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within the filtered data set were then generated by taxonomic binning via the
Quantitative Insights Into Microbial Ecology tool (Qiime) and its various
components (104). Open reference OTU picking was performed via Usearch
6.1 software (105) using 97% similarity to the clustered Greengenes
database from August 2013 (106) while removing singleton OTUs from the
OTU table as further quality filtering to improve specificity. The taxonomic
classifications of sequence reads were identified from the phylum to the
species level by the uclust based consensus taxonomy classifier (Bokulich,
Rideout et al. (submitted)) with phylogenetic tree creation by Fast Tree
(107). For diversity measures, an even sequence sampling depth of 16,000
sequences was used to avoid artifacts due to differing numbers of
sequences per sample. PCoA analyses were performed to compare
microbial community structure between samples utilizing weighted UniFrac
measures (108). Linear effect size (LefSe) analyses were performed using
the freely distributed Galaxy LefSe analysis module hosted at
huttenhower.sph.harvard.edu/lefse/ (109). Hypothesis testing using the
Dirichlet-Multinomial Distribution was performed via the HMP package for R
(110) within the R Statistical Computing Environment (111)
I. Statistical Analysis
Results are reported as means ± standard error mean (SEM; n = 4-7).
ANOVA with Bonferroni’s post-hoc test (for parametric data) or Mann-Whitney
Rank Sum test (for nonparametric data) was used for the determination of
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statistical significance among treatment groups, as appropriate. A p value less
than 0.05 was selected before the study as the level of significance.
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CHAPTER III
OLIGOFRUCTOSE PROTECTS AGAINST ENHANCED LIVER INJURY
CAUSED BY ARSENIC IN A MODEL OF HIGH FAT DIET INDUCED NONALCOHOLIC STEATOHEPATITIS – ROLE OF THE ECM

A. Introduction
Exposure to high concentrations of arsenic (As) is associated with a myriad of
health effects including skin lesions, hypertension, cardiovascular disease,
respiratory disease, and malignancies of the skin and internal organs (112). The
liver, a major site of arsenic metabolism, is a known target of arsenic toxicity
(113). Indeed, chronic arsenic exposure causes hepatomegaly, non-cirrhotic
portal fibrosis and portal hypertension (113-115). The concentrations of arsenic
found in the US water supply are generally considered lower than those
necessary to cause overt liver damage, however lower levels of arsenic can
cause more subtle changes in the liver (46) and can sensitize the liver to injury
by another insult (47). Therefore, while arsenic levels in the US may not be high
enough to directly injure the liver, there is evidence that low levels of arsenic may
interact with other risk-modifying factors to cause hepatic injury.
Obesity is another major health concern for the US and globally. More than
one third of American adults are obese (116), and it is expected that the number
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of obese individuals in the US will double by 2050 (117). Obesity is associated
with a myriad of health effects including insulin resistance, diabetes, and nonalcoholic fatty liver disease (NAFLD). NAFLD is a spectrum of disease states
including simple steatosis, non-alcoholic steatohepatitis, and fibrosis and
cirrhosis. Studies have shown that about 20-30% the general population has
NAFLD (118) however studies have shown that the prevalence of NAFLD can
more than double in obese cohorts (119). Despite the high incidence of NALFD
in obese populations, only a minority of obese individuals ever progress to more
severe stages of liver disease, such as non-alcoholic steatohepatitis. Risk
factors for primary NAFLD include obesity, type II diabetes and dyslipidemia
(120). However it is likely that other unidentified risk factors contribute to
progression to more severe stages of liver disease (i.e. NASH).
Interestingly, there is potential overlap in areas of risk for arsenic exposure
and obesity. For example, rural communities, which have both artesian water
supplies that are unregulated by Clean Water Act, often have high arsenic
concentrations; these areas also generally have a high prevalence of obesity. In
a study investigating the possible interaction between obesity and arsenic, this
group demonstrated that low levels of arsenic synergistically enhance liver
damage caused by high fat diet (98). These data suggest that underlying risk
factors, such as obesity, may modify the risk of hepatic injury caused by
subhepatotoxic levels of arsenic exposure. However, the mechanism(s)
underlying enhanced liver injury remain unknown.
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The role of the gut:liver axis in liver disease is well recognized. Indeed, liver
injury is associated with dysbiosis, disruption of gut barrier integrity, and leakage
of inflammatory bacterial-derived components (i.e., endotoxin) from the gut into
the systemic circulation. Obesity can affect gut permeability by decreasing the
barrier function of the epithelium (78). Additionally, both obesity and arsenic
have been shown to alter gut flora (121). Interestingly, probiotics, live bacteria
cultures which promote commensal bacteria growth, can preserve intestinal
barrier integrity and protect against liver injury in animals (81, 122). Clinical
studies have shown that probiotic supplementation improves patient outcome
compared to standard therapy (123) via gut-mediated mechanisms. Prebiotics,
dietary compounds that favor the growth and maintenance of commensal
bacteria, may also confer protective effects in the setting of liver injury via gutmediated mechanisms. For example, Cani et al showed that the prebiotic
oligofructose (OFC) can protect against inflammation and endotoxemia by
regulating the microbiota of animals fed high fat diet (78). Recently, arsenic
exposure has been shown to also cause dysbiosis in mice (124), which could, in
principle, exacerbate the effect of HFD. The purpose of the current study was to
test this hypothesis and to determine if the prebiotic oligofructose can protect
against enhanced liver injury caused by arsenic in a mouse model of NAFLD.
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B. EXPERIMENTAL PROCEDURES
1. Animals and treatments
Animals were exposed to combinations of HFD, arsenic and the prebiotic
oligofructose as described in Chapter II.
2. Clinical Chemistry
Plasma levels of ALT and AST were determined as described in Chapter II
3. Lipid determination
Lipids were extracted from snap-frozen liver as described in Chapter II.
Triglycerides and non-esterified fatty acids were determined as described in
Chapter II.
4. Immunostaining
Hematoxylin and eosin staining, immunohistochemical staining for F4/80 and
immunofluorescent staining for fibrin were performed on liver tissue as described
in Chapter II.
5. RNA isolation and real-time PCR
Details for RNA isolation and real time PCR are described in Chapter II.
6. Cecal DNA extraction
DNA was extracted from cecal content as described in Chapter II.
7. Microbiome analysis
Metagenomic analysis of the cecal microbiome was performed as described
in Chapter II.
8. Statistical analysis
Statistical analysis was performed as described in Chapter II.
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C. Results
1. Body and organ weight
All animals gained weight and there was no mortality or morbidity in any
group during the course of the study. As observed previously (98), arsenic did
not significantly affect food consumption or body mass gain in animals fed either
LFD or HFD (Figure 3.1A and B). High fat diet significantly increased food
consumption ~20% and body mass gain ~50% compared to low fat diet alone
(Figure 3.1C). Whereas OFC supplementation did not affect food consumption, it
did significantly attenuate the increase body mass gain caused by HFD; this
effect of OFC was independent of the presence of arsenic in the diet.

2. OFC protects against liver Injury
HFD significantly increased the percent liver to body weight compared to low
fat diet (Figure 3.2B). Liver weight to body weight percent was not significantly
affected by concomitant arsenic exposure or by oligofructose feeding. As
expected by the hepatomegaly observed, 10 weeks of HFD feeding dramatically
increased lipid accumulation in the liver (Figure 3.2A); this pathologic change
comprised both macrovesicular and microvesicular steatosis. Changes in
quantity of hepatic triglycerides and non-esterifieid fatty acids (NEFA) (Figure
3.2B) were also determined. HFD alone increased hepatic triglyceride and NEFA
content compared to LFD alone by more than 4 fold. Arsenic administration did
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Figure 3.1: Model parameters
(A) Animals were exposed to arsenic (or tap) water for 11 weeks. One week after
the start of arsenic exposure experimental diet (e.g. LFD, HFD, or HFD +OFC)
was provided as described in Chapter II. (B) Body weight and food consumption
were recorded once per week for the duration of the experiment. Data are
shown as +/- SEM (n = 6-10). a, p < 0.05 compared to tap water control; b, p <
0.05 compared to LFD; c, p < 0.05 compared to no OFC.
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Figure 3.2: OFC protects against liver injury and steatosis.
(A) Representative photomicrographs depicting hematoxylin & eosin staining
(H&E, 200x; top left) are shown (B) Liver to body weight percent (LW/BW%) was
determined as described in Materials and Methods. Hepatic non-esterified fatty
acid (NEFA) and triglyceride (TG) content (top right) were determined using kits
as described in Materials and Methods. Plasma levels of alanine and aspartate
aminotransferase were determined as an index of liver injury. Quantitative data
are shown as +/- SEM (n =6-10). a, p < 0.05 compared to tap water control; b, p
< 0.05 compared to LFD; c, p < 0.05 compared to no OFC.
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not affect steatosis or hepatic triglyceride or NEFA content when, in either LFDor HFD-fed animals. Oligofructose administration blunted fat accumulation and
significantly decreased triglyceride content compared to animals that received
either HFD or arsenic + HFD without OFC. Interestingly, OFC had no significant
effect on NEFA content of the liver.
HFD feeding also increased the appearance of necroinflammatory foci in the
liver (Figure 3.2A). Circulating levels of the liver enzymes alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) were determined
as indices of liver damage (Figure 3.2B). HFD alone significantly increased ALT
levels, but did not significantly affect AST levels. Whereas arsenic did not
significantly affect plasma levels of either ALT or AST in the LFD group, it
significantly enhanced the increase in these variables caused by HFD under
these conditions by ~50%. The addition of OFC to animals receiving HFD did not
affect the transaminase levels in the absence of arsenic. However, OFC
administration completely blunted the increase in both ALT and AST caused by
the combined exposure of arsenic and HFD.

3. OFC protects against inflammation
Immunohistochemistry for F4/80, a marker of activated macrophages, was
performed as an index of inflammation (Figure 3.3A). Neither arsenic nor HFD
alone altered the number of F4/80 positive macrophages; however the
combination of arsenic + HFD significantly increased the number of hepatic
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Figure 3.3: OFC protects against hepatic inflammation.
(A) Representative photomicrographs of immunohistochemical staining for F4/80
(200x) are shown. (B) Number of F4/80 positive cells were counted per 1000
hepatoctyes as described in Chapter II. C. Real time RT-PCR was performed for
the pro-inflammatory geneTNFα as described in Chapter II. Data are shown as
+/- SEM (n = 6-10). a, p < 0.05 compared to tap water control; b, p < 0.05
compared to LFD; c, p < 0.05 compared to no OFC.
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macrophages compared to arsenic or HFD alone, as was observed previously
(98). The administration of OFC significantly blunted the increase in number of
activated macrophages caused by the combination of arsenic and HFD and
values were similar to those of LFD controls.

4. OFC protects against fibrin deposition
Previously, the enhancement of HFD-induced liver injury caused by arsenic
correlated with a significant increase in hepatic expression of PAI-1 (98). PAI-1
is a major inhibitor of both tissue-type plasminogen activator (tPA) and
urokinase-type plasminogen activator (uPA), and is therefore a key inhibitor of
fibrin degradation (i.e., fibrinolysis) by plasmin. Fibrin deposition was determined
by immunofluorescent staining and quantitation of fluorescent signal. LFD-fed
animals given either tap or arsenic-containing water had minimal fibrin deposition
in the liver (Figure 3.4A). HFD alone increased deposition of fibrin by ~2-fold. As
observed previously (98), the combination of HFD + arsenic significantly
increased the expression of PAI-1 and fibrin deposition in liver (Figure 3.4B).
OFC administration almost completely prevented the changes caused by arsenic
under these conditions.

5. Effects on the microbiome
The effects of arsenic, HFD, and OFC on relative abundance and total
abundance of bacteria was determined at the phylum level (Figure 3.5A). As
expected, the most abundance bacteria phyla were Bacteroidetes and
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Figure 3.4: OFC protects against sinusoidal fibrin accumulation.
A. Representative photomicrographs (400x) of immunofluorescent staining for
fibrin are shown. B. Fibrin immunofluorescence (green color) was quantitated
using Metamorph software. C. Hepatic PAI-1 mRNA expression was
determined using real time RT-PCR. Data are shown as +/- SEM (n = 6-10). a, p
< 0.05 compared to tap water control; b, p < 0.05 compared to LFD; c, p < 0.05
compared to no OFC.

47

A

a,b

40000

30000

Hepatic mRNA Expression
(fold of control)

Fibrin Fluorescence
(pixels/field)

B

a

20000

c

c

10000

0

HFD
As
OFC

6

b

PAI-1

4

2

0

-

+
-

+
-

+
+
-

+
+

+
+
+

HFD
As
OFC

48

-

+
-

+
-

+
+
-

+
+

+
+
+

Firmicutes. Arsenic exposure alone caused a loss of the Verrucobiorobia in
animals that were fed a LFD. Interestingly, this effect was lost in animals that
were fed a HFD; however, the combination of arsenic and HFD did lead to an
increase in the gram-negative phyla Bacteroidetes. Oligofructose feeding
increased the relative abundance of Bacteroidetes with a concomitant decrease
in Firmicutes compared to all other groups that did not receive the prebiotic.
Additionally, OFC restored the growth of Tenericutes which was lost in animals
that received a HFD. OFC also resulted in a robust increase in total bacteria
compared to animals that did not receive OFC.
α diversity (Figure 3.5B) was used as a measure of diversity within a sample.
Interestingly, the greatest α diversity was observed in animals exposed to a LFD.
HFD feeding reduced α diversity and the combination of HFD and OFC resulted
in the lowest α diversity of all six groups. β diversity was used as a measure of
diversity between samples (Figure 3.5C). As expected, samples that represent a
single treatment group clustered more closely together, suggested a higher
degree of similarity among the samples.
Linear discriminant analysis effect size (LefSe) was used to identify the
enrichment of bacteria within treatment groups. When all six treatment groups
were compared, unique enrichment profiles were observed for each group
(Figure 3.6A). In a LefSe comparison between the LFD and LFD + arsenic,
enrichment was primarily seen in animals that received tap water, suggesting
that arsenic exposure resulted in decreases in these bacteria including the
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Figure 3.5: Effects of HFD, arsenic, and OFC on bacterial abundance and
diversity.
A. The top stacked bar chart shows the relative abundance of bacteria phyla for
each group. Absolute abundance (bottom) was determined by averaging the
total number of OTUs found in each bacterial phyla per group. B. Alpha diversity,
a measure of unique OTUs present in a given sample, is shown as an index of
diversity within a sample. Alpha rarefaction curves were determined by counting
the number of sequences found in a sampling of bacterial DNA. During the first
sampling, all sequences identified were counted towards the number of observed
OTUs; for each additional sampling, only unique OTUs are counted and added to
the number of observed OTUs for that sample. This process is repeated until a
total of 16,000 sequences are sampled. C. Beta diversity is shown as a measure
of diversity between samples. This measure was determined using principle
coordinate analysis of the phylogenetic diversity between samples and the
differences in OTU abundance between samples. Samples that are closer in
proximity have microbiomes that are more similar in term of phylogenetic
diversity and OTU abundance.
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Figure 3.6: HFD, arsenic, and OFC exposure caused unique changes to the
microbiome.
LefSe analysis was used to determined enrichment of taxa between groups.
Effect size is determined using linear discriminant analysis (LDA). A. LefSe
analysis of all six treatment groups is plotted on a cladogram. Each treatment
group is represented by a unique color; highlighted taxa indicate enrichment of
that taxa within the treatment group. Effect size is represented by the size of the
circular intersection points between the taxa. B. Bar plot of LefSe analysis
comparing the gut microbiomes of animals fed either LFD or a LFD and arsenic
(top). Each bar represents a bacterial taxa that was enriched by LFD. The
length of the bar represents the effect size. C. Bar plot of LefSe analysis
comparing the gut microbiomes of animals fed either HFD (blue), HFD and
arsenic (red), or HFD, arsenic, and OFC (green). The length of the bar
represents effect size.
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commensal Bifidobacterium (Figure 3.6B). Comparisons between animals fed
HFD with or without arsenic and OFC showed that arsenic exposure was
associated with a decrease in Mogibacteriacaceae and Turicibacter (Figure
3.6C).

D. DISCUSSION
The GI tract is home to approximately 100 trillion gut microbes (125). The
microbes residing in the gut regulate many important physiological functions
including metabolic processing, energy production, and immune system
development (125). Therefore, it is not surprising that dysbiosis of the gut flora is
associated with a myriad of disease states locally in the GI tract including
diarrhea/malabsorption (126, 127) and irritable bowel disease (128, 129).
Because of the critical importance of the microbiome in immune surveillance and
tolerance, changes in the gut microbiome are also linked to autoimmune and
diseases (130-132). The gut microbiome does not only contribute to diseases of
the GI tract. Indeed, several studies indicated that distal organ systems,
including the CNS, are negatively affected by gut dysbiosis (133).
A major mechanism by which gut dysbiosis may contribute to systemic
disease is via changing/impairing the GI tract barrier function. For example,
rodent models of obesity have been associated with altered gut microbiota that
favor gut leakiness (78, 79) and endotoxemia (78, 80). Furthermore, dysbiosis
associated with obesity contributes to the development of inflammation (78, 80)
metabolic syndrome (134, 135), and non-alcoholic fatty liver injury (79). The
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understanding that the GI tract contributes to liver injury (i.e., the gut-liver axis)
has been understood for over a century and was first shown experimentally more
than 60 years ago by Rutenberg et al, when they demonstrated that
nonabsorbable antibiotics protected against diet-induced liver injury (136). Since
then, many studies using a myriad of models including antibiotics (137, 138), and
germ-free mouse models (139) have provided additional evidence implicating the
microbiome in the susceptibility and development of liver disease. Today, the
gut-liver axis and enteric dysbiosis, including that caused by a HFD, is a
generally accepted component in the development of liver disease.
Although the role of arsenic in altering the microbiome is less well studied,
arsenic is known to alter the microbial components of soil (140). A recent study
by Lu et al has shown that high levels of arsenic can cause dysbiosis in mice
(124). In their study, metagenomic analysis of the gut flora of mice exposed to
50 ppm arsenic showed that arsenic significantly altered the abundance of some
microbial families and also resulted in functional changes in the microbiome’s
metabolic profile (124). The changes in the gut flora caused by arsenic in the
current study were more subtle than those seen by Lu and colleagues; this
difference may be attributed, in part, to the >10-fold lower arsenic concentrations
used in the current study. Nevertheless, arsenic exposure did change the mouse
microbiome in the current study; importantly, arsenic further exacerbated the
dysbiosis caused by HFD feeding in mice. Importantly, supplementation with
oligofructose, a prebiotic that has been demonstrated to protect against dysbiosis
and favor commensal bacteria, almost completely prevented the enhancement of
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HFD-induced liver injury caused by arsenic. These results therefore support the
hypothesis that arsenic mediates liver injury under these conditions via
mechanisms that involve the gut-liver axis.
There are several potential mechanisms by which the microbiome may
mediate arsenic-induced liver injury. First, the changes in the microbiome
caused by diet (HFD and OFC) may affect arsenic metabolism and absorption.
Indeed, interactions between gut microbes and arsenic are bidirectional. For
instance, Pinyayev et al showed that bacteria from the mouse cecum can
metabolize arsenic (141) and others have shown that the human gut flora can
metabolize arsenic into toxic metabolites (142, 143). Whereas this is distinctly
possible, it should be noted that concentrations that are 10-fold higher than used
here were not directly hepatotoxic (47). Alternatively, the effects of arsenic on
the microbiome may mediate the observed hepatotoxicity. Indeed, arsenic
exposure expanded the population of Gram negative bacteria that could produce
endotoxins, which are well known for contributing to fatty liver injury. However,
whether the effects are driven by microbiome changes on arsenic levels, or by
arsenic changes on the microbiome, these changes may potentiate arsenic
toxicity locally on the gut epithelium (144) and contribute to enhanced arsenic
toxicity distally in the liver.
In addition to direct effects on the microbiome, the protective effect of OFC
feeding under these conditions could also be ‘upstream’ of arsenic. Specifically,
OFC feeding significantly attenuated the increase in hepatic lipids caused by
HFD, both in the presence and absence of arsenic. The multi-hit hypothesis of
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fatty liver disease involves not only an increase in gut-derived products that
damage the liver, but also an increased sensitivity to the damage caused by
these gut-derived products. Indeed, fatty livers are more sensitive to a second
toxic ‘hit,’ including gut-derived LPS (145, 146). Therefore, the favorable effects
of OFC on hepatic steatosis may indirectly protect against the injury caused by
HFD and/or arsenic by blunting this sensitization. In support of this hypothesis,
enhanced liver injury caused by arsenic + HFD co-exposure was not due to an
increase in steatosis per se, but rather due to an enhanced hepatic inflammatory
response. Therefore, OFC may also be protecting against damage in this model
by preventing hepatic sensitization caused by HFD-induced endotoxemia. Such
a mechanism is supported by previous studies that arsenic-exposed livers are
more sensitive to exogenous LPS (47) and that liver injury here in OFC-fed mice
was insensitive to arsenic administration.
In conclusion, protection against enhanced liver injury conferred by OFC is
likely due to both direct effects on the microbiome, as well indirect effects on
hepatic sensitization. These findings are in-line with previous work, in which
OFC supplementation was shown to protect against direct effects of HFD on the
gut microbiome and barrier function (80). Prebiotics favor an environment in
which commensal bacteria can thrive, in lieu of direct delivery of commensal
bacteria (i.e., probiotics). As such, this approach may yield more predictable and
stable results. Nevertheless, these results serve proof-of-principle that protecting
against microbiome changes caused by arsenic can prevent the enhancement of
inflammatory liver injury caused by this environmental contaminant.
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CHAPTER IV
CHARACTERIZATION OF THE LINK BETWEEN LIVER AND LUNG INJURY
IN THE SETTING OF ALCOHOL EXPOSURE – THE ROLE OF TNFα

A. Introduction
Alcohol use is widespread in the United States with more than half of
Americans reporting alcohol consumption on a weekly basis (147). It has long
been known that chronic ethanol consumption can lead to development of a
myriad of health effects spanning a variety of organs including the brain, gut, liver
and lungs. Indeed, the effects associated with chronic alcohol consumption have
made alcohol the third leading risk factor globally for disease and disability (148)
at a cost of more than $166 billion annually to treat the medical consequences of
alcohol abuse (33). Despite the known health risks, alcohol consumption remains
pervasive in today’s culture. In toto, alcohol consumption is responsible for ~6%
of all disability-adjusted life years (DALY) lost in the United States (149), most of
which are attributable to alcohol-induced toxicity.
The liver is well recognized as a major target of alcohol-induced organ injury.
This is due in part to the high concentrations of alcohol reached in the portal
blood as well as the detrimental effects of ethanol metabolism (e.g., oxidative
stress). Alcoholic liver disease (ALD) is actually a spectrum of disease states
that include simple steatosis (fat accumulation), steatohepatitis, and in more
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severe cases fibrosis and cirrhosis. A major focus in ALD therapy is to treat the
decompensation associated with end-stage ALD (i.e., cirrhosis). Indeed, the
sequelae of a failing liver (e.g., ascites, portal hypertension, and hepatorenal
syndrome) are generally what causes death in end-stage ALD. Although the
successful treatment of these secondary effects prolongs the life of ALD patients,
this therapy is only palliative; there are currently no therapies to halt or prevent
the progression of ALD.
Alcohol consumption can also contribute to lung damage. In contrast to the
liver, alcohol consumption does not appear to directly cause any overt pulmonary
pathology; however, alcohol is known to exacerbate the severity of lung damage
from other causes. It has been estimated that up to 190,000 people suffer from
acute lung injury (ALI) annually in the United States (52). The risk of developing
more severe forms of ALI such as acute respiratory distress syndrome (ARDS) is
significantly higher in people who meet the diagnostic criteria for alcohol use
disorders (53). Whereas alcohol consumption does not cause overt pathology in
the lung, studies have shown that experimental alcohol exposure can lead to
subtle changes to this organ, which has been coined the ‘alcoholic lung
phenotype.’ This effect of alcohol is characterized by dysregulated inflammatory
response (55, 56), oxidative stress (58, 150), and tissue remodeling (59, 60).
The dysregulated inflammatory response caused by alcohol in the lung is
dependent on both the amount and duration of alcohol consumption and is
suspected to be a key player in alcohol-related lung dysfunction (61). The exact
mechanisms that mediate the development of the alcoholic lung phenotype and
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increased risk of ALI/ARDS remain unclear. Better understanding of this
complex process could identify potential therapeutic targets to treat or prevent
alcohol-related lung dysfunction, such as ALI/ARDS.
It is now clear that many human diseases are a multi-stage, multi-hit process;
it is therefore not surprising that multiple cells within a target organ contribute to
disease pathology. Indeed, system level analyses of disease, and organ-organ
interactions, are again gaining the attention of the research community. Several
studies indicate interdependence between liver and lung in organ pathology. For
example, mortality in ALI in the setting of severe hepatic disease is almost 100%
(151). In experimental models of liver injury, vascular permeability and leukocyte
activation in lungs are increased (152). Studies investigating the multi-organ
effects of endotoxemia indicate that interaction between the liver and lung are not
only likely, but may occur via alcohol-induced mediators (75) including TNFα
(76), an inflammatory cytokine markedly increased in ALD (77).
The purpose of this study was to characterize a model of concomitant liver
and lung injury in the setting of chronic alcohol exposure. It was hypothesized
that chronic alcohol exposure acts as a first ‘hit’ that sensitizes these organs to a
second inflammatory stimulus (e.g., bacterial lipopolysaccharide; LPS). The
parallel mechanisms of liver and lung injury in this ‘2-hit’ model were explored.
Furthermore, the potential interdependence of liver and lung injury via systemic
release of TNFα was also determined.

60

B. Experimental procedures
1. Animals and treatments
Animals were exposed to ethanol and/or LPS as described in Chapter II.
Some animals also received the TNFα blocker etanercept as described in
Chapter II.
2. Histology
Liver and lung tissue was stained with hematoxylin & eosin and chloroacetate
esterase as described in Chapter II.
3. Clinical Chemistry
Serum levels of alanine aminotransferase (ALT) and aspartate
aminostransferase (AST) were determined using standard kits as described in
Chapter II.
4. RNA isolation and real-time RT-PCR
RNA was isolated from liver and lung tissue as described in Chapter II. Real
time RT-PCR was performed for the genes TNFα, IL-6, IL-10, KC, MIP-2, and
the endogenous control β-actin as described in Chapter II.
5. Luminex
Luminex technology was used to determine the levels of TNFα, IL-10, MIP-2,
and KC in the plasma and BAL as described in Chapter II
6. Statistical analysis
Data were analyzed as described in Chapter II.
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C. Results
Throughout the duration of dietary exposure, all mice gained ~0.6 g/week, with
no differences between dietary and treatment groups. In saline-treated mice fed
control diet, liver weights (as percent of body weight) were 4.7± 0.1 g, whereas
ethanol-fed mice had liver weights of 4.8 ± 0.2 g. Liver weights in both groups
were unchanged by LPS exposure.

1. Ethanol-induced steatosis enhanced LPS-induced liver injury
As expected, 6 wks exposure to EtOH-containing diet caused mild liver
damage, characterized predominantly by microvesicular fat accumulation in
midzonal regions of the liver (Figure 4.1A; H&E staining). LPS administration to
pair-fed animals increased the accumulation of inflammatory foci in liver.
Feeding EtOH-containing diet increased the severity and frequency of
necroinflammatory foci caused by LPS administration. Plasma levels of alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) were determined
as indices of liver injury (Figure 4.1B). Chronic ethanol exposure significantly
increased ALT and AST levels in the plasma. LPS alone did no significantly
affected circulating levels of ALT or AST. The combination of ethanol exposure
and LPS significantly increased plasma ALT and AST 4 hours after LPS
administration; 24 hours after LPS administration, AST values remained
significantly elevated compared to controls
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Figure 4.1: Effects of chronic ethanol pre-exposure on LPS induced liver
injury and inflammation.
(A) Representative photomicrographs of liver tissue after hematoxylin & eosin
staining (200x; H&E) and chloroacetate-esterase staining (400x; CAE). (B)
Plasma levels of alanine-aminotransferase (ALT; black bars) and aspartateaminotransferase (AST; grey bars) were used as an index of liver injury. (C)
Quantitation of hepatic neutrophil content. Data are shown as +/- SEM a, p <
0.05 compared to pair fed controls, b p < 0.05 compared to LPS alone.
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In addition to hematoxylin and eosin staining, Figure 4.1 also shows staining for
neutrophils using chloroacetate esterase staining (CAE staining). Chronic
ethanol exposure did not significantly affect neutrophil infiltration compared to
their pair-fed counterparts (Figure 4.1A, right panels). As was expected, LPS
increased the number of neutrophils in the liver compared to vehicle controls.
Ethanol pre-exposure dramatically enhanced neutrophil infiltration caused by
LPS.

2. Ethanol enhanced LPS-induced lung injury and inflammation
In liver, LPS injection caused noticeable pathologic changes as early as 4 h
after administration (Figure 4.1A). Pathology in the lung tissue was also changed
as early as 4 h as evidenced by inflammatory damage, however alveolar
hemorrhage was not observed until the 24 hour timepoint (Figure 4.2). At this
timepoint, LPS increased areas of alveolar hemorrhage in the lung, which can be
observed in H+E staining, as indicated by an increase in the number of red blood
cells in the pulmonary interstitium (Figure 4.2A, left panels). Hemorrhage was
macro-heterogeneous, with some areas exhibiting a higher degree of
hemorrhaging than others. Analogous to findings in liver, EtOH enhanced LPSinduced lung damage, as characterized by an increase in the frequency and
severity of alveolar hemorrhage caused by LPS. The increase in alveolar wall
thickness caused by LPS also appeared to be more pronounced after ethanol
exposure. CAE staining of the lung tissue showed a significant increase in
neutrophils in the lung tissue 4 h after LPS administration. Chronic ethanol
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Figure 4.2: Effects of chronic ethanol pre-exposure on LPS induced lung
injury and inflammation.
(A) Representative photomicrographs of lung tissue after hematoxylin & eosin
staining (400x; H&E) and chloroacetate-esterase staining (400x; CAE). (B) Cell
number in the bronchioalveolar lavage fluid (BALF). (C) Quantitation of
pulmonary neutrophil content. Data are shown as +/- SEM a, p < 0.05 compared
to pair fed controls, b p < 0.05 compared to LPS alone.
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exposure enhanced the effect of LPS at the 4 hour timepoint. Incidentally, 24
hours after LPS administration, neutrophil infiltration persisted, but was no longer
significantly different between ethanol and pair-fed groups.

3. Ethanol differentially alters cytokine/chemokine expression in the liver
and lung
The pathologic assessment of liver (Figure 4.1) and lung (Figure 4.2)
indicates that chronic ethanol exposure enhanced the inflammation and damage
caused by LPS in both organs caused by LPS. To further characterize the
mechanisms by which ethanol causes these effects, the mRNA expression of key
inflammatory mediators (TNFα, IL-6, IL-10, PAI-1, MIP-2, and KC) were
determined via real time RT-PCR (Figure 4.3A). Chronic alcohol exposure alone
caused no significant changes in mRNA expression of these select cytokines in
either the liver or lung. However, LPS administration alone significantly
increased hepatic mRNA expression of TNFα, IL-6, IL-10, PAI-1, and MIP-2, with
PAI-1 and MIP-2 being the most robustly induced; LPS did not significantly affect
the hepatic mRNA expression of KC. As expected, chronic ethanol exposure
enhanced the increase in TNFα and IL-6 mRNA expression levels seen with LPS
alone in the liver.
Similar to the results seen in the liver, LPS administration alone increased the
pulmonary mRNA expression of all mediators; however, the increase in TNFα
was much less pronounced compared to liver and MIP-2 was the inflammatory
mediator that was most robustly altered. In contrast to the liver, chronic ethanol
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Figure 4.3: Effect of chronic ethanol exposure on LPS-induced cytokine
expression.
(A) Cytokine mRNA expression in the liver and lung at the four-hour LPS time
point. (B) Inflammatory cytokine levels in the plasma and bronchoalveolar fluid
(BALF) at the four-hour time point. Data are shown as +/- SEM a, p < 0.05
compared to pair fed controls, b p < 0.05 compared to LPS alone.
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exposure did not significantly enhance the increase in TNFα expression seen
with LPS alone. However, ethanol did enhance the increases in IL-6, PAI-1, and
MIP-2 mRNA caused by LPS in the lung, but the pattern of that enhancement
differed from liver tissue. Indeed the increase in MIP-2 caused by EtOH + LPS in
the lung was >2-fold higher than observed in the liver. Additionally, ethanol
exposure significantly enhanced the increase in expression of KC in the lung, an
effect not observed in liver tissue.
The liver is the major contributor to the increase in inflammatory mediators in
plasma in response to i.p. LPS administration (153). Likewise, BALF contains
inflammatory mediators produced by lung tissue. The presence of the select
mediators (TNFα, IL-10, MIP-2 and KC) in the plasma and BALF were therefore
determined via Luminex assay (Figure 4.3B). With the exception of IL-10 in the
BALF, LPS treatment increased the levels of all four inflammatory mediators in
the plasma and BALF. In plasma, chronic ethanol exposure enhanced the
increase in systemic IL-10 and TNFα caused by LPS, but did not significantly
affect MIP-2 and KC. In contrast, TNFα and IL-10 levels in the BALF were both
insensitive to ethanol preexposure, but the increase in MIP-2 and KC caused by
LPS administration was dramatically enhanced.

4. Effect of etanercept on indices of injury and inflammation.
Previous studies have established that TNFα production is critical for
subsequent pulmonary chemokine (e.g., MIP-2 and KC) production and injury in
experimental models of ARDS (154). It is unclear, however, whether the source
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of TNFα needs to be pulmonary or systemic in order to see this effect in the
lungs (155). Therefore, etanercept was used to deplete systemic TNFα, then
measured the effects of etanercept on indices of damage and inflammation in the
liver and lung. As seen in Figure 4, co-administration of etanercept during the
course of the study partially protected against liver injury, as determined by AST
levels (Figure 4.4B), but did not affect steatosis or inflammation caused by
ethanol or LPS (Figure 4.4A), respectively. Etanercept administration decreased
levels of freely soluble TNFα in response to the combination of LPS in the
plasma and BALF, by 33% and 60%, respectively. Interestingly, etanercept
administration caused a 1.3-fold decrease in plasma MIP-2 levels which
correlated with a decrease in MIP-2 mRNA expression in the liver. Etanercept
also caused decreased MIP-2 in the BALF as well as a 3.2-fold decrease in KC
levels in the BALF. The decrease in BALF KC levels correlated with a 3.5-fold
decrease in pulmonary KC mRNA expression.

D. Discussion
It is now generally accepted that human disease can be a multi-stage, multihit process in which various cells within a target organ contribute to disease
pathology. In addition to cell-cell interactions within a single organ, recent
studies have begun to highlight the importance of more complex interactions,
including those between multiple organs. One example of such inter-organ
interaction in the setting of alcohol exposure is the critical link between the
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Figure 4.4: Etanercept protects against enhanced cytokine levels in the
BALF without concomitant protection against liver injury.
(A) Representative photomicrographs of liver tissue (200x; top) and lung tissue
(400x; bottom) after hematoxylin & eosin staining. (B) Fold change in indices of
liver injury (ALT, AST), plasma and pulmonary cytokine levels, and mRNA
expression in the liver and lung. Data are shown as +/- SEM a, p < 0.05
compared to no etanercept.
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intestine and the liver, or the gut-liver axis (156). Indeed, a myriad of
experimental and clinical studies have demonstrated that alcohol-induced gut
dysbiosis and subsequent impairment of the gut barrier results in the release of
gut-derived toxins (e.g. LPS) and endotoxemia (157-159). Studies using
antibiotics (137), germ-free mouse models (160), and probiotics (161) have
confirmed that endotoxemia caused by alcohol consumption drives injury in
experimental models of ALD. Today, the gut-liver axis and enteric dysbiosis is a
widely-accepted component in the development of ALD as well as other liver
disease (156, 162).
This group is particularly interested in potential interactions between the liver
and lung, i.e. the liver-lung axis, in the context of alcohol exposure. As
mentioned in the introduction, liver disease is associated with increased
incidence of acute lung injury and enhanced mortality. These and other findings
have suggested a potential interaction between the liver and lung that may
represent an important aspect of the pathophysiology of acute lung injury,
particularly in the setting of sepsis. Bringham and collaborators tested the
possible interaction between the liver and lung in a study performed in an in situ
perfused piglet preparation (152). Their model revealed that hypoxemia and
pulmonary edema were only observed when the liver and lung circulations were
connected. Their results indicate that while endotoxemia could directly cause
pulmonary vasoconstriction and leukocyte sequestration, interaction between the
liver and lung was required for severe inflammatory response and oxidative injury
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to the lung. Additional studies have also shown that pulmonary injury induced by
systemic endotoxin can be altered by mediators released from the liver (e.g.
TNFα) (84, 152). Unfortunately, few studies have investigated the potential
interactions between the liver and lung in the setting of chronic alcohol exposure.
Therefore the goal of this study was to characterize a model of concomitant liver
and lung injury caused by LPS after chronic ethanol administration. The LieberDecarli model of chronic alcohol administration was chosen for this study
because this model has been used previously to study effects of alcohol
exposure on both the liver (163-167) and lung (62, 168, 169), albeit separately.
Systemic LPS administration served as an inflammatory stimulus to induce
hepatic inflammation and an ARDS-like phenotype in the lung.
The effects of the Lieber-DeCarli rodent model of ethanol exposure on the
liver is well-characterized and is predominated by hepatic steatosis (163). Six
weeks of exposure to the Lieber-Decarli diet does not cause overt liver injury or
hepatic inflammation (163), but sensitizes the liver to other toxic stimuli. In this
study, LPS served as an inflammatory insult that induces hepatic inflammation
and injury. In this 2-hit model, alcohol pre-exposure enhanced liver injury and
inflammation, which corroborates previous findings in this model. Ethanol
exposure has been shown to prime immune cells, including Kupffer cells, to
release cytotoxic mediators including TNFα after stimulus (77, 170, 171). In this
study enhanced liver injury correlated with enhanced mRNA expression and
plasma levels of TNFα in response to LPS, which previous studies have shown
to be predominantly derived from Kupffer cells (172).
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Acute lung injury is associated with increased release of pro-inflammatory
cytokines (173) in the lung and neutrophil migration into the interstitium (174). In
this study, ethanol pre-exposure enhanced alveolar hemorrhage and neutrophil
infiltration caused by LPS. Studies have shown that neutrophil migration into the
lung is at least partially mediated by the chemokines MIP-2 and KC (175-177).
Indeed, both MIP-2 and KC have been linked to acute lung injury caused by
systemic LPS (178, 179) by mediating neutrophil recruitment via activation of
CXCR2 (180). The work presented here shows that LPS-induced MIP-2 and KC
expression in the lung was enhanced by ethanol exposure. Furthermore,
increases in these chemokines correlated with increased neutrophil recruitment.
Interestingly, increased expression of MIP-2 and KC in the lung and BAL have
been shown to be downstream of TNFα signaling (88), which was not enhanced
by ethanol pre-exposure in the lung in our model. In contrast, hepatic TNFα
mRNA expression and systemic levels of TNFα were enhanced by the
combination of ethanol + LPS. As mentioned previously, the role of Kupffer cellderived TNFα in liver injury is well recognized (181-183), however hepaticderived TNFα has also been shown to contribute to pulmonary injury. A study by
Kono et al demonstrated that depletion of hepatic Kupffer cells protected against
pulmonary inflammation and injury and correlated with decreased TNFα
expression (183). These findings suggest that systemic inflammation mediated
by increased release of TNFα by hepatic macrophages (i.e. Kupffer cells), may
be partially responsible for driving pulmonary MIP-2 and KC expression, and
subsequent pulmonary injury, as presented here.
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In order to determine the role of systemic/hepatic TNFα in enhanced
pulmonary injury, the effect of depleting systemic TNFα with etanercept was
determined. Etanercept is a fusion protein of the human p75 TNF receptor and
the Fc portion of human IgG1. This TNFα binding antibody has been approved
by the FDA for treatment of rheumatoid arthritis and psoriasis. In the work
presented here, etanercept administration resulted in a 1.7 and 1.9 fold decrease
in systemic and pulmonary TNFα levels, respectively, compared to animals that
were exposed to ethanol + LPS in the absence of etanercept. This incomplete
blocking of systemic and pulmonary TNFα was likely due to the robust increase
in TNFα caused by systemic LPS administration, particularly in the plasma; in
fact, LPS administration caused more than a 10 fold increase in systemic TNFα
levels compared to their vehicle-treated, ethanol-fed counterparts. Despite the
lack of complete TNFα knockdown, etanercept decreased TNFα levels in the
plasma by >100 pg/mL.
Etanercept under these conditions provided partial protection against
inflammatory injury in the lung caused by the combination of ethanol and LPS.
Etanercept administration blunted enhanced MIP-2 and KC levels in the lung,
resulting in a 1.6 and 3.5 fold decrease, respectively. These results support
previous findings that TNFα signaling was upstream of enhanced MIP-2
expression in experimental ARDS (184). The authors of that study showed that
TNFR1-/- mice were partially protected against increased MIP-2 expression in a
model of acute lung injury (184). Whereas the protective effect of TNFα
depletion was significant, it was not complete. Indeed, TNFα is likely one of
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several factors that may contribute to the ‘alcoholic lung phenotype. For
example, PAI-1 has been linked to liver and lung injury (29, 50, 185) and was
differentially affected by ethanol pre-exposure in this model. Additionally,
oxidative stress and transitional tissue remodeling are known to play important
roles in liver injury and inflammation. Therefore, complete protection against
injury in either organ will likely require multiple interventions or an intervention
that protects against multiple mechanisms of injury (i.e., Kupffer cell blockade).
Nevertheless, these results establish a strong link between systemic TNFα and
lung damage in this model of alcohol-enhanced ARDS.
As mentioned above, the priming effect of ethanol on the hepatic
inflammatory response is relatively well established. In contrast, the effect of
ethanol exposure on lung has predominantly focused on impaired bacterial
clearance and subsequent increased susceptibility to pulmonary infections (186188). Indeed, others have shown that ethanol preexposure impairs alveolar
macrophage function and inflammatory cytokine release (168, 189, 190).
However, there are two important differences between the current study and
those that have reported decreased immune response after alcohol. Specifically,
the timing of LPS administration has been shown to play an important role in
alcohol-induced liver injury. Previous studies have shown that if LPS is
administered during acute alcohol intoxication (or w/in 1 day of a bolus dose of
alcohol), the hepatic inflammatory response is blunted. In contrast, if LPS is
given distal to alcohol intoxication, the inflammatory response is synergized
(170). Indeed, most studies that have documented a decrease in pulmonary
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immune response in the context of alcohol exposure used acute models of
intoxication in which LPS was administered within hours of alcohol exposure
(186, 191-194). Indeed, others have shown that chronic alcohol exposure can
enhance pulmonary inflammation post-intoxication. For example, a recent study
by Liu et al showed that chronic ethanol exposure enhances the pulmonary
inflammatory response caused by insult (195). Additionally, Boe et al showed
that chronic ethanol exposure enhances LPS-induced neutrophil migration, as
was observed in the current study (196). Therefore it is likely that the timing of a
stimulus – whether during intoxication or distal to intoxication – plays a critical
role in pulmonary response after alcohol exposure. This timing effect could
create a ‘perfect storm’ in the lung that clearance of infection is impaired during
alcohol intoxication, but the inflammatory response and normal tissue damage
caused by that infection is enhanced later. Such a paradigm would explain the
fact that ethanol exposure increases both the incidence of lung infections and the
likelihood of developing ARDS in response to a lung infection in the human
population.
In conclusion, the current study characterizes a model of alcohol-induced liver
and lung sensitization which enhances injury caused by systemic LPS. These
data suggest that the pulmonary response to ethanol is dependent on systemic
release of TNFα, most likely from the liver (Figure 4.5). Additionally, although
ethanol pre-exposure enhanced both liver and lung inflammation, both organs
experienced a unique pro-inflammatory cytokine profile indicating that similar, yet
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Figure 4.5 Proposed mechanism of interdependent injury.
This work supports the hypothesis that systemic TNFα plays an important role in
enhanced pulmonary injury caused by the combination of chronic ethanol
exposure and LPS. The combination of ethanol and LPS caused significant
increases in hepatic TNFα. Interestingly, the combination of ethanol and LPS
caused a significant increase in MIP-2 mRNA expression and protein levels in
the lung tissue and BAL, respectively. Previous studies have shown that MIP-2
expression in the lung is driven, at least in part, by TNFα signaling. The work
here demonstrated that depleting systemic TNFα with etanercept partially
protects against increased MIP-2 expression the lung. This protection against
MIP-2 correlated with protection against pulmonary injury.
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distinct, mechanisms may be contributing to injury in these two organs. Other
studies have suggested that injury to the liver and lung may be linked, potentially
via systemic mediators such as TNFα. Enhanced MIP-2 and KC expression in
the lung, without a concomitant increase in pulmonary TNFα further support a
potential role for hepatic-derived TNFα as a mediator of pulmonary injury in this
model. Since etanercept is already approved for human use for treatment of
rheumatoid arthritis and psoriasis, the translational value of these findings is
high.
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CHAPTER V
ROLE OF THE EXTRACELLULAR MATRIX IN THE LIVER IN A MODEL OF
CHRONIC ALCOHOL EXPOSURE

A. Introduction
The extracellular matrix (ECM) consists of a diverse group of proteins and
sugars including collagens, glycoproteins and proteoglycans. Together, these
fibrous macromolecules create a scaffold that provides structure to tissues and a
substratum for cells. In addition to their structural role, these ECM components
serve as signaling molecules via interactions with cell-surface receptors and
impact cell-to-cell communication by binding and retaining soluble mediators
including cytokines, chemokines, and growth factors (3). Proteases and
protease inhibitors present in the ECM serve as regulators of matrix degradation
important for the maintenance of the ECM homeostasis as well as remodeling of
the matrix composition in disease (2). Together, the diverse range of the ECM
components work bi-directionally with surrounding cells to create a dynamic and
responsive microenvironment that regulates cell signaling, recruitment and tissue
function.
The role of the ECM is well established in the setting of chronic liver injury,
such as alcoholic liver disease (ALD). Indeed, robust changes in the hepatic
ECM is the hallmark of later stages of liver disease (fibrosis and cirrhosis) which
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are characterized by dramatic increases in collagen deposition (197). Given the
dominance of collagenous changes in the hepatic ECM during fibrosis/cirrhosis,
many studies have focused on the mechanisms underlying changes in collagen
deposition that lead to hepatic fibrosis. However, the alterations of the hepatic
ECM during fibrosis are much more diverse than simply an increase in collagen,
and include changes in the deposition and distribution of a myriad of other ECM
proteins (e.g., laminin and vitronectin), that may also contribute to fibrogenesis
(48).
Hepatic ECM changes are not only more diverse than simply changes to
collagen, but also not only relegated solely to fibrogenesis per se. Indeed, it is
becoming increasingly understood that the hepatic ECM responds dynamically to
stress. For example, changes in the expression of ECM proteins such as
fibronectin (28, 90), and fibrin (29, 49, 50) have been observed in models of
hepatic inflammation. Importantly, blocking these ECM changes blunts, at least
in part, hepatic injury in these models. Therefore, transitional changes to the
ECM may contribute to early disease initiation and/or progression long before
fibrosis phases of liver disease.
Currently there exists a great need to characterize qualitative and
quantitative changes in the ECM protein composition in earlier stages of disease
that may be targeted for therapeutic benefit (198). Although previous studies
have shown that subtle changes in the ECM may contribute to the development
of inflammatory liver injury, the research in this area has thus far been restricted
to the hypothesis-driven study of single ECM components. A more ‘omic
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approach has been previously hampered by the difficulties associated with the
low abundance and insolubility of many ECM proteins. Therefore, a goal of this
study was to develop a multi-step liver extraction that would allow for the
enrichment and solubilization of ECM proteins. A second goal of this work was
to use proteomic analysis to determine global changes in the extracellular matrix
in a model of inflammatory liver damage.

B. Experimental procedures
1. Animals and treatment
Animals were exposed to ethanol and/or LPS as described in Chapter II
2. ECM extraction
Liver tissue was submitted to a 3-step extraction process that allows
sequential isolation of loosely-bound extracellular proteins, cellular proteins,
tightly bound extracellular proteins, and highly crosslinked, insoluble proteins to
be differentially separated as described in Chapter II.
3. LC-MS analysis.
Liver tissue extracts underwent liquid chromatography and mass spec
analysis as described in Chapter II
4. Analysis
LC-MS data was analyzed as described in Chapter II
5. Statistical analysis
Statistical analysis was performed as described in Chapter II.
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C. Results
For this study, a previously described 3-step ECM fractionation method was
adapted for use with mouse liver tissue (95-97). The ECM isolation method was
performed on hepatic tissue of from and a model of ASH which does not cause
significant fibrosis. Three sequential extraction steps were used in order to
reduce cellular protein contamination and allow for greater resolution of low
expressing ECM proteins (Figure 5.1).
The first step of the extraction involved treatment with 0.5 M NaCl. This step
removes loosely-bound proteins by displacing polyionic interactions between
proteins. The ECM proteins extracted during this step likely include newly
formed and/or degraded ECM components and ECM-binding proteins that are
loosely associated with the matrix (e.g., proteins that bind to ECM
glycosaminoglycans; (199). Following NaCl extraction, the remaining liver tissue
was decellularized using 1% SDS. This step solubilizes cytoplasmic and nuclear
membranes, allowing for the release of cellular proteins. Decellularization was
followed by a denaturing step with 4 M guanidine HCl (GnHCl) buffer (200).
Following the denaturing extraction, an insoluble pellet enriched in highly
insoluble, heavily cross-linked matrix proteins (i.e. type I collagens) remains (96).
All three extracts as well as the insoluble pellet were subjected to enzymatic
deglycosylation with chondroitinase ABC, endo-beta-galactosidase, and
heparitinase II to remove the side chains chondroitin, keratin, and heparin sulfate
of glycoproteins, respectively. This step increases the chance of proper
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Figure 5.1: Scheme of extraction methodology.
Liver tissue from pair-fed (control) animals and animals exposed to ethanol, LPS,
or the combination of ethanol + LPS underwent increasingly vigorous extraction
with a NaCl buffer, SDS buffer, and GnHCl buffer as described in Materials and
Methods.
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identification of proteoglycans by mass spectroscopy, which are infamous for
being heavily post-translationally modified.
1. Analysis of LC-MS data
After LC-MS analysis (see Materials and Methods), Scaffold proteome
software was used for visualization of the MS data. Across the four experimental
groups, the NaCl extract contained 588 proteins, the SDS extract contained 511,
the GnHCl extract contained 585, and the pellet contained 322 proteins. The
Scaffold software allows classification of total proteins by gene ontology (GO)
annotation. When sorted by GO annotation, the NaCl contained 89 extracellular
proteins, the SDS extract contained 63, GnHCl contained 84, and pellet
contained 46 extracellular proteins. Additional analysis was only performed on
those proteins that were classified as extracellular proteins by GO annotation.
The extracellular proteins identified by GO annotation were further categorized
into four classes based on their role in the extracellular space as determined by a
comprehensive literature search. These four groups include class 1)
glycoproteins and proteoglycans, class 2) other ECM-associated proteins class
3) proteases and protease inhibitors and class 4) collagens. If no record could
be found supporting the hypothesis that a protein was associated with the ECM,
the protein was placed into a fifth group, class 5) other proteins. Table 5.1 shows
a list of all the proteins from this study that were identified by GO annotation as
extracellular, the classification of the extracellular proteins, and references
supporting their association with the ECM.
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Table 5.1: Extracellular proteins

Accession
Number

Protein name
Proteoglycans and glycoproteins

MW
(kDa)

ECM function

Ref

Alpha-1-acid glycoprotein 1

A1AG1_MOUSE

24

Acute phase serum protein

(201)

Alpha-2-HS-glycoprotein

FETUA_MOUSE

37

Inhibitor of ECM mineralization

(202)

ARSA_MOUSE

54

ECM structure

(203)

Beta-2-glycoprotein

APOH_MOUSE

39

Coagulation, phospholipid
binding

(204)

91

Arylsulfatase A

Biglycan

PGS1_MOUSE

42

Regulation of collagen fibril
formation, ECM-cell
interactions

(205)

Corneodesmosin

CDSN_MOUSE

54

Adhesive protein

(206)

Cysteine-rich with EGF-like
domain protein 2

CREL2_MOUSE

38

Extracellular protein heavily
glycosylated. ECM
function unknown

(207)
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█
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█

█

█

█
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Decorin

Dermatopontin

Dystroglycan

Fibrinogen alpha chain

PGS2_MOUSE

DERM_MOUSE

DAG1_MOUSE

E9PV24_MOUSE

40

24

97

87

ECM-cell interactions, ECM
assembly

ECM-cell interactions, ECM
assembly

Matrix organization, basement
membrane assembly

Hemostasis, cell signaling
(fibrin(ogen) alpha chain)

(208)

(209)

(210)

(211)

FIBB_MOUSE

55

Hemostasis, cell signaling

(211)

Fibrinogen gamma chain

FIBG_MOUSE

49

Hemostasis, fibrinogen
polymerization

(212)

92

Fibrinogen beta chain

Fibronectin

Galectin-1

Galectin-3-binding protein

FINC_MOUSE

LEG1_MOUSE

LG3BP_MOUSE

273

15

64

Scaffolding, ECM organization,
regulation of ECM-cell
interactions

(213)

Matrix crosslinking, matrix
organization

(214)

Cell-matrix adhesion

(215)
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Granulins

GRN_MOUSE

63

Cell-matrix signaling

(216)

Haptoglobin

HPT_MOUSE

39

Inhibition of collagen
degradation, cell migration

(217)

Insulin-like growth factorbinding
protein 2

IBP2_MOUSE

33

Binding/retainment of ILGF in
the extracellular space

(218)

Insulin-like growth factorbinding protein 4

IBP4_MOUSE

28

Binding/retainment of ILGF in
the extracellular space

(218)

K1C13_MOUSE

48

Cell-matrix adhesion, cell
migration

(219)

Leucine-rich HEV
glycoprotein

Q91XL1_MOUSE

37

Cell-matrix adhesion

(220)

Lumican

LUM_MOUSE

38

Regulation of collagen fibril
formation

(221)

93

Keratin, type I cytoskeletal 13

Microfibrillar-associated
protein 5
Fibrinogen alpha chain

MFAP5_MOUSE

E9PV24_MOUSE

18

87

Elastic fiber assembly, binding
of fibrillin-1 and fibrillin-2

Hemostasis, cell signaling
(fibrin(ogen) alpha chain)

(222)

(211)

NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet

█
█
█

█
█
█

█
█
█

█
█
█

█
█
█

█
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█
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█
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█

█

█
█

█
█
█

█
█

█
█

█

█

█

█
█
█

█

█
█
█

█
█
█
█

Ribonuclease inhibitor

RINI_MOUSE

50

Extracellular inhibitor of
angiogenin which can
degrade BM

(223)

Sulfated glycoprotein 1

SAP_MOUSE

61

Cell survival, cell signaling

(224,
225)

Syndecan-4

SDC4_MOUSE

21

ECM organization, signal
transduction, cell adhesion

(226)

Tubulointerstitial nephritis
antigen-like

TINAL_MOUSE

52

Protein binding - fibronectins,
collagens

(227)

Vitronectin

VTNC_MOUSE

55
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Other ECM-associated proteins
14-3-3 protein epsilon

1433E_MOUSE

29

ECM-cell signal transduction,
cell adhesion

Protein binding

(228)

(229)

NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet

█

█
█
█
█
█

█
█
█
█
█
█

█
█
█
█
█
█

█
█
█
█
█
█

█

█

█

█

█

█

█

█

█

█

█

█

█

Con
NaCl

█

EtOH

█

█

LPS

█

EtOH
+LPS

█

SDS
GnHCl

14-3-3 protein gamma

14-3-3 protein sigma

1433G_MOUSE

1433S_MOUSE

28

28

Protein binding

Protein binding

(229)

(229)

Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet

█

█

█

█
█

█

█

█

█

█

14-3-3 protein zeta/delta

1433Z_MOUSE

28

Protein binding

(229)

Actin, cytoplasmic 1

ACTB_MOUSE

42

Cortical cytoskeleton

(230,
231)

Actin, cytoplasmic 2

ACTG_MOUSE

42

Cortical cytoskeleton

(230,
231)

Alpha-2-macroglobulin
receptorassociated protein

AMRP_MOUSE

Alpha-actinin-4

ACTN4_MOUSE

105

Focal adhesion, cell adhesion

(233,
234)

Annexin A1

ANXA1_MOUSE

39

ECM binding, fibrinolysis

(235)

42

Protein binding, soluble
mediator internalization

(232)

95
Annexin A2

ANXA2_MOUSE

39

ECM binding, fibrinolysis

(236)

Annexin A5

ANXA5_MOUSE

36

ECM binding (collagen)

(237)

Apolipoprotein A-I

APOA1_MOUSE

31

ECM binding (collagen,
fibronectin)

(238)
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Apolipoprotein A-IV

Apolipoprotein E

APOA4_MOUSE

APOE_MOUSE

45

36

Lipid metabolism

Lipid metabolism, cell signaling

(239)

(240)

APOOL_MOUSE

29

Beta-2-microglobulin

B2MG_MOUSE

14

Protein binding, cell-ECM
interaction

(241)

Calreticulin

CALR_MOUSE

48

Protein binding (collagens,
laminin)

(242)

Calumenin

CALU_MOUSE

37

Pprotein binding, stabilization of
fibulin-1

(243)

Carbonic anhydrase 2

CAH2_MOUSE

29

pH regulation of ECM (other
isozymes)

(244)

Ceruloplasmin

CERU_MOUSE

121

Iron, copper binding

(245)

Chitinase-like protein 3

CHIL3_MOUSE

44

ECM turnover

(246)
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Apolipoprotein O-like
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Clusterin

Cofilin-1

CLUS_MOUSE

COF1_MOUSE

52

19

Extracellular protein chaperone

Cortical cytoskeleton, cell
motility

(247)

(248)

C-reactive protein

CRP_MOUSE

25

Protein binding (fibronectin)

(249)

C-X-C motif chemokine 9

CXCL9_MOUSE

14

Soluble mediator (angiostatic
cytokine)

(250,
251)

ENPL_MOUSE

92

Soluble mediator (TLR
signaling)

(252)

Estradiol 17-betadehydrogenase 12

DHB12_MOUSE

35

Protein binding (heparin,
fibronectin, collagen)

(253)

Ferritin heavy chain

FRIH_MOUSE

21

Cell migration

(254)

Ferritin light chain 1

FRIL1_MOUSE

21

Cell migration

(254)

Glucose-6-phosphate
isomerase

G6PI_MOUSE

63

Cell motility

(255)
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Endoplasmin
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Hepatoma-derived growth
factor
High mobility group protein
B1

HDGF_MOUSE

HMGB1_MOUSE

26

25

Decreted heparin-binding
growth factor

Heparin binding, cytokine

(256)

(257,
258)

HMGB2_MOUSE

24

Heparin binding, cytokine

(257,
258)

Lumican

LUM_MOUSE

38

Regulation of collagen fibril
formation

(221)

Moesin

MOES_MOUSE

68

Cell cortex organization

(259)

Myosin-9

MYH9_MOUSE

226

Cell migration, cortical actin
organization

(260)

Neutrophil gelatinaseassociated
lipocalin

NGAL_MOUSE

23

ECM remodeling (modulation of
MMP9 activity)

(261)

Nucleobindin-2

NUCB2_MOUSE

98

High mobility group protein
B2

Peptidyl-prolyl cis-trans
isomerase A

PPIA_MOUSE

50

18

Matrix maturation

Matrix assembly of hensin

(262)

(263)
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Pro-cathepsin H

CATH_MOUSE

37

Matrix degradation

(264)

S100-A13

S10AD_MOUSE

11

Calcium binding

(265)

S100-A9

Serum amyloid A-1

Serum amyloid A-2

SAA1_MOUSE

SAA2_MOUSE

14

14

Cell adhesion

Cell adhesion

(266)

(266)

99
Serum amyloid A-3

SAA3_MOUSE

14

Cell adhesion

(266)

Serum amyloid P-component

SAMP_MOUSE

26

Protein binding (type IV
collagen, laminin)

(267,
268)

Superoxide dismutase [CuZn]

SODC_MOUSE

16

Protein binding
(heparin/heparan sulfate,
type 1 collage)

(269)

Thioredoxin

THIO_MOUSE

12

Soluble mediator
(immunomodulatory
cytokine)

(258)

NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet

█

█

█

█

█

█

█

█

█

█
█
█

█
█
█

█
█
█

█

█

█

█
█
█

█
█
█

█

█

█
█

█

█
█

█
█
█
█
█

█
█
█
█
█

█
█
█
█
█

█
█
█
█
█

█
█

█
█

█
█

█
█

Tubulin beta-5 chain

TBB5_MOUSE

50

Microtubule formation, modified
via ECM interactions

(231)

UPF0556 protein C19orf10
homolog

CS010_MOUSE

18

Soluble mediator (cytokine)

(270)

Vimentin

VIME_MOUSE

54

Microtubule formation

(271)

Vitamin D-binding protein

VTDB_MOUSE

54

Vitamin D binding

(272)
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EtOH
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Proteases and protease inhibitors
Alpha-1-antitrypsin 1-1

A1AT1_MOUSE

46

Inhibition of ECM proteases;
inhibition of trypsin

(273)

NaCl

█

GnHCl

Alpha-1-antitrypsin 1-4

A1AT4_MOUSE

46

Inhibition of ECM proteases;
inhibition of trypsin

AMBP

AMBP_MOUSE

39

Precursor of protein HC
(protein-ECM interactions) &
bikunin (protease inhibitor),

(274276)

Inhibition of ECM proteases,
inhibition of ADAMTS-7
and ADAMTS-12

(277)

Alpha-2-macroglobulin

A2M_MOUSE

166

█

█

SDS

(273)
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Antithrombin-III

Cathelin-related
antimicrobial peptide

ANT3_MOUSE

CRAMP_MOUSE

52

20

Inhibition of ECM proteases,
inhibition of thrombin

(278)

Inhibition of ECM proteases,
inhibition of cathepsin Lcysteine protease activity

(279)

Cathepsin B

CATB_MOUSE

37

ECM degradation

(264)

Cathepsin D

CATD_MOUSE

45

ECM degradation, activation of
cathepsin B

(280)

CATZ_MOUSE

34

ECM degradation, integrin
signaling

(281,
282)

Complement C3

CO3_MOUSE

186

Activation of complement
system

(283)

Dipeptidyl peptidase 4

DPP4_MOUSE

87

Protein cleavage (cytokines,
chemokines), protein
binding (collagen)

(284)

101

Cathepsin Z

Ectonucleoside triphosphate
diphosphohydrolase 5

ENTP5_MOUSE

47

Hydrolysis of extracellular ATP

(285)

Fetuin-B

FETUB_MOUSE

43

Cysteine protease inhibitor,
metalloprotease inhibitor,
matrix mineralization

(286,
287)
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Gelsolin

GELS_MOUSE

86

Actin filament capping

(288)

Ectonucleoside triphosphate
diphosphohydrolase 5

ENTP5_MOUSE

47

Hydrolysis of extracellular
ATP/ADP (signaling)

(286)

Hemopexin

HEMO_MOUSE

51

Heme binding

(289)

102

Insulin-degrading enzyme

IDE_MOUSE

118

Metalloendopeptidase

(290)

Inter alpha-trypsin inhibitor,
heavy chain 4

ITIH4_MOUSE

100

Chain of ITI (protease inhibitor)

(291)

Lysozyme C-1

LYZ1_MOUSE

17

Antibacterial, hydrolysis of β-1,
4-glycosidic linkages

(292)

Lysozyme C-2

LYZ2_MOUSE

17

Antibacterial, hydrolysis of β-1,
4-glycosidic linkages

(292)

Murinoglobulin-1

MUG1_MOUSE

165

Protease inhibitor

(293,
294)

Myeloid bactenecin (F1)

O08692_MOUSE
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Cysteine protease inhibitor

(295)
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Phosphatidylethanolaminebinding protein 1
Plasminogen

PEBP1_MOUSE

PLMN_MOUSE

21

91

Serine protease inhibitor

Precursor of plasmin (serine
protease)

(296)

(297)

103

Probable carboxypeptidase
PM20D1

P20D1_MOUSE

56

Serpinb9

O08797_MOUSE

42

Serine protease inhibitor,
granzyme inhibitor)

(298)

Serine protease inhibitor
A3K

SPA3K_MOUSE

47

Serine protease inhibitor,
chymotrypsin inhibitor

(299)

Serine protease inhibitor
A3N

SPA3N_MOUSE

47

Serine protease inhibitor,
chymotrypsin inhibitor

(299)

Serpin B5

SPB5_MOUSE

42

Serine protease inhibitor,

(299)

Thioredoxin

THIO_MOUSE

12

Activation of transglutaminase

(300)

Transthyretin

TTHY_MOUSE

16

Hormone binding protein,
cryptic protease,
peptidase

(301)
(302)
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Collagens
Adiponectin

ADIPO_MOUSE

27

Inhibition of vascular matrix
degradation (contains
collagen-like domain)

(303,
304)

CO1A1_MOUSE

138

Component of collagen fibrins

(303)

Collagen alpha-1(III) chain

CO3A1_MOUSE

139

Component of collagen fibrils

(303)

CO4A1_MOUSE

161

Component of collagen network

(303)

104

Collagen alpha-1(V) chain

CO5A1_MOUSE

184

Fibrillogenesis, crosslinking

(303)

Collagen alpha-2(I) chain

CO1A2_MOUSE

130

Component of collagen fibrils
(contains collage-like
domain)

(303)

Collagen alpha-2(IV) chain

CO4A2_MOUSE

167

Component of collagen network

(303)

Collagen alpha-2(V) chain

CO5A2_MOUSE

145

Fibrillogenesis, crosslinking

(303)

Mannose binding protein

MBL2_MOUSE

26

soluble pattern recognition
receptor

EtOH

LPS

EtOH
+LPS
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Collagen alpha-1(I) chain

Collagen alpha-1(IV) chain
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Extracellular - ECM interactions unknown
60 heat shock protein,
CH60_MOUSE
mitochondrial

61

105

78 glucose-regulated
protein

GRP78_MOUSE

72

Aminoacyl tRNA synthase
complex-interacting
multifunctional
protein 1
Arginase-1

AIMP1_MOUSE

34

ARGI1_MOUSE

35

BolA-like protein 1

BOLA1_MOUSE

14

BolA-like protein 3

BOLA3_MOUSE

12

Carboxylesterase 1C

EST1C_MOUSE

61

Clathrin heavy chain 1

CLH1_MOUSE

192

Epididymal secretory protein
E1

NPC2_MOUSE

16

Group XIIB secretory
phospholipase A2-like
protein
Heat shock cognate 71
protein

Q8VC81_MOUSE

22

HSP7C_MOUSE

71

Hepcidin

HEPC_MOUSE

9

Hypoxia up-regulated protein
1

HYOU1_MOUSE

111

106

Interferon-inducible GTPase
1

IIGP1_MOUSE

48

Lactotransferrin

TRFL_MOUSE

78

Macrophage migration
inhibitory factor

MIF_MOUSE

13

Major urinary protein 12

A2CEK7_MOUSE

21

Major urinary protein 17

MUP17_MOUSE

21

Major urinary protein 20

MUP20_MOUSE

21

Major urinary protein 3

MUP3_MOUSE

21

Major vault protein

MVP_MOUSE

96

Monocyte differentiation
antigen CD14

CD14_MOUSE

39

Multiple coagulation factor
deficiency protein 2
homolog
Myeloperoxidase

MCFD2_MOUSE

16

PERM_MOUSE

81

Nuclease-sensitive elementbinding protein 1

YBOX1_MOUSE

36

Polymeric immunoglobulin
receptor

PIGR_MOUSE

85

Profilin-1

PROF1_MOUSE

15

107

Protein CREG1

CREG1_MOUSE

24

Protein Gm20425

E9Q035_MOUSE

108

Pyruvate kinase PKM

KPYM_MOUSE

58

RNA binding motif protein,
X-linked-like-1

RMXL1_MOUSE

42

Serotransferrin

TRFE_MOUSE

77

Serum albumin

ALBU_MOUSE

69

Serum
paraoxonase/arylesterase
1
Translationally-controlled
tumor protein

PON1_MOUSE

40

TCTP_MOUSE

19

UPF0369 protein C6orf57
homolog

CF057_MOUSE

12

Xanthine
dehydrogenase/oxidase

XDH_MOUSE

147

2. 3-step serial extraction creates 4 extracts with distinct protein
profiles
For initial analysis, the ECM proteins present in each of the four extracts
from control animals was compared (Figure 5.2, top) without regard to protein
classification. Each extract had a unique extracellular protein profile consisting of
not only ECM proteins that were shared among all four extracts (7), but also
proteins unique to particular extracts. Indeed, there were 16, 3, 15, and 7
proteins unique to the NaCl, SDS, GnHCl, and pellet fractions, respectively in
livers from control animals. These results indicate that the extraction approach
was effective at separating the proteins.
When ECM proteins were compared between treatment groups,
interesting patterns of protein presence in the extracts were revealed (Figure 5.3,
lower). For example, some proteins (e.g., plasminogen), if present, located
consistently to the same extraction fraction across the treatment groups. The
effect of treatments on other proteins was more complex than the simple
presence and absence. For example, whereas annexin A1 was found in the
insoluble pellet in samples from control animals, it was absent in the liver from
animals exposed to ethanol or LPS alone; however, the combination of ethanol
and LPS caused this protein to accumulate in the NaCl fraction. Likewise,
although fibrin(ogen) gamma chain peptides were found in all treatment groups,
the location of these signals was unique to each treatment condition. These
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Figure 5.2: Liver extracts have unique protein profiles based on fraction
type and experimental group.
The number of proteins unique to or shared by all four extractions of pair-fed
animals is shown (A). Bubble graphs are used to show presence of
plasminogen, annexin A1 and fibrin(ogen) gamma chain across the four extracts
(x-axis) and the four experimental groups (y-axis).
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changes likely represent differences in the synthesis, degradation and/or maturity
of the ECM proteins.
3. Qualitative changes to the ECM proteome in response to stress
The highest abundance of ECM was found in the GnHCl fraction of the
control liver, which was closely followed by the NaCl fraction. Of the proteins in
the NaCl and SDS extracts the majority were ECM-associated proteins (class 2;
Figure 5.3); this effect was expected as these are generally loosely associated
with the extracellular matrix and are easily solubilized. Additionally, the low
abundance of collagens (class 3) in the NaCl and SDS fractions was not
surprising as collagens are often tightly cross-linked and require denaturing
conditions for solubilization. As expected, the denaturing conditions created by
GnHCl more than doubled the number of proteoglycans and glycoproteins in the
GnHCl extract compared to the NaCl and SDS fractions. The number of
collagens in the GnHCl extract were also dramatically increased compared to the
NaCl and SDS fractions. The pellet fraction contained the fewest proteins of all
four extracts; this fraction has the greatest number of collagens (8) which are
known to be highly cross-linked to the point of insolubility (306). These results
indicate that the 3 step extraction process was successful in separating and
enriching the ECM proteins.
Exposure to ethanol and LPS, alone or combined, did not change the
general pattern of proteins found in the various extracts (Figure 5.3), but both
tended to increase the number of ECM proteins. For example, ethanol exposure
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Figure 5.3: Ethanol and LPS cause dynamic changes in the matrisome.
Each row represents a separate extract and each column represents a separate
experimental group comparison. In the left column, the number of proteins
unique to the control (blue) or ethanol (yellow) groups and the number of proteins
shared between the two experiment groups (green) in toto (Venn diagram) or
separated by protein class (stacked bar graph) are shown. Similarly, in the right
column, Venn diagrams show the total number of proteins unique to control
(blue) or LPS (yellow) group and shared between these two groups (green) and
stacked bar graphs show changes in protein number by protein class. The size
of the Venn diagrams are proportional to the number of proteins represented.
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caused a net increase in the number of ECM proteins by ~22%. These changes
were spread across the first 3 protein classes [(1) proteoglycans and
glycoproteins, (2) ECM associated proteins, and (3) protease and protease
inhibitors] with the NaCl, SDS and GnHCl extracts all increasing to a similar
extent. The least responsive protein class were the collagens (class 4), which
did not show a net increase with ethanol or LPS exposure. Likewise, the pellet
fraction responded the least dynamically to ethanol or LPS exposure, and
actually showed a net loss in total proteins. Figure 5.4 (left panels), shows the
distribution of the proteins in the various extracts between all 4 treatment groups.
In addition to proteins that changed in their extraction pattern in response
to ethanol (e.g., see Figure 5.2, lower panel), there were 22 proteins whose
presence was unique to ethanol exposure compared to control; these include
fibrin(ogen) α and β chains, cytokeratin 13, vitronectin, plasminogen, high
mobility group protein B2, and collagens IVα2 and Vα2. Likewise, LPS exposure
caused the appearance of several proteins that were unique compared to control.
Eighteen of these proteins were shared with ethanol exposure (e.g., fibrin(ogen)
α and β chains, cytokeratin 13, vitronectin, plasminogen, high mobility group
protein B2, and collagen IVα2), but also 14 that were unique to LPS compared to
ethanol, including serpin B5 (maspin), serine protease inhibitor A3N (Serpin
A3N), and CXC motif chemokine 9 (CXCL9).
Previous work has shown that ethanol pre-exposure sensitizes the liver to
inflammatory injury caused by a second insult (i.e. LPS) (170, 307).
Furthermore, previous studies have suggested that changes in the ECM
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composition can contribute to the sensitizing effect of ethanol pre-exposure (29,
50, 308). In this study, the combination of chronic ethanol exposure and a
second hit of LPS caused unique changes in the ECM protein profile of the liver.
Indeed, the combination of EtOH + LPS resulted in the appearance of 4 unique
proteins that were not present in livers from animals exposed to either ethanol or
LPS alone, including serum amyloid P and serpine B9.
4. Quantitative changes to the extracellular proteome caused by stress.
The composition of extracellular environment is tightly regulated and drastic
changes, such as the presence or absence of ECM proteins, can produce
functional changes in the surrounding tissue. Therefore, it was not surprising
that the presence of the majority (73 proteins) of the extracellular matrix proteins
was not altered by any exposure regardless of fraction type. However, several
proteins that did not change qualitatively changed in abundance. In order to
understand better the more subtle changes on the expression of extracellular
proteins in the four fractions, quantitative changes in the expression that were not
changed qualitative was determined (Figure 5.4, right panels).
Several proteins change quantitatively in response to ethanol and/or LPS
exposure relative to control animals in the livers. Notable (>4-fold increase)
changes caused by LPS included ferritin heavy chain (15-fold increase) in the
NaCl fraction, haptoglobin and myosin-9 (11- and 9-fold, respectively) in the SDS
fraction, and fibrinogen γ chain and haptoglobin (14- and 7-fold, respectively) in
the GnHCl fraction. Notable changes caused by ethanol include myosin-9 (6-
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Figure 5.4: Liver extracts show quantitative changes in the matrisome.
Venn diagrams (left column) show all proteins within an extract and indicate the
number that are shared between or that are unique to the four experimental
groups. Bubble plots (right column) show quantitative changes in protein
expression of proteins that were shared by all four experimental groups. The
bubble plots show fold change in protein expression caused by LPS (y-axis),
ethanol (x-axis), and the combination of ethanol + LPS (bubble size). Each
bubble represents a single extracellular protein; bubble color indicates the
protein’s class.

116

117

fold) and cysteine-rich with EGF-like domain protein 2 (CREDL2; 6-fold) in the
SDS fraction. As was observed for qualitative analysis (Figure 5.3), the pellet
fraction was the most stable of the fractions with very few changes in the
expression level of ECM proteins.
Some proteins responded to the combination of ethanol and LPS
exposure differentially than a simple additive effect. For example, although LPS
alone did not change endoplasmin levels and ethanol only increased it 3-fold, the
combination of ethanol and LPS increased this protein 11-fold in the NaCl
fraction. A similar effect was seen on granulin expression in the SDS fraction,
which was increased by 5-fold by LPS + ethanol despite no effect by ethanol
alone and only a 2-fold increase by LPS. Additionally, although both LPS and
ethanol alone increased CRELD2 the combination of ethanol + LPS actually
decreased the levels in the SDS fraction. In the GnHCl fraction, proteins that
were differentially regulated by the combination of ethanol and LPS include
hemopexin and alpha-1-microglobulin/bikunin precursor (AMPB).
D. Discussion
The aim of this work was to develop and characterize a method of hepatic
ECM protein extraction and analysis that would provide both the sensitivity to
identify low expression proteins and the power to observe global changes in the
ECM using proteomics. As mentioned in the Introduction, the study of the
hepatic ECM proteome (i.e., matrisome) has largely been ‘collagenocentric’ and
‘fibrisocentric – that is, centered on the dramatic increase in collagen deposition
during fibrosis, a quasi-permanent scarring of the organ. However, the
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matrisome of the healthy and diseased liver is significantly more diverse than
collagen ECM. Indeed, studies have shown that in addition to collagen, laminin
(306) and vitronectin (309, 310) are also increased during fibrogenesis.
Furthermore, proteomic-based studies in other organs haves demonstrated that
the matrisome responsds dynamically in composition after insult (95-97).
Previously, this group showed that fibrin ECM accumulation correlates with
inflammatory liver injury in several models, and may well play a causal role (29).
Additionally, Gillis et al. have shown a similar role for fibronectin ECM in
experimental ALD (28). However, little is known about global changes in the
hepatic ECM during inflammatory liver injury.
Global changes in the ECM may mediate tissue function via mechanisms
that fall generally into three categories, including physical, biochemical, and
signaling. Physical properties of the ECM include the matrix topography,
organization, and crosslinking (2). These physical properties support the
structural role of the ECM, but can also allow regulation of cell migration both by
serving as a physical barriers or enhancer to that function (26). For example,
fibrin matrices are permissive to chemotaxis and activation of monocytes and
leukocytes (311, 312). Physical changes in the ECM can cause tissue rigidity
resulting in reduced organ function. Although such physical changes to the ECM
can of course indirectly influence the biochemistry of the liver (e.g., hemostasisinduced hypoxia), changes to the mastrisome can also directly cause
biochemical changes that are independent of structural changes. For example,
ECM components can facilitate interactions between ligands and receptors (313),
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bind and retain chemokines (3), and regulate activation of growth factors (i.e.
TGFβ, (3). ECM molecules also can serve directly as signaling molecules via
interactions with cell surface receptors, including integrins (314). Because of the
multi-faceted roles of many ECM molecules, any single change in the
extracellular matrix can trigger a cascade of dependent changes that influence
the composition and properties of the ECM. For example, biglycan serves as a
structural component which regulates collagen fiber assembly but upon release
from the matrix by can serve as a signaling molecule binding to TLR4 receptors
(315).
In the current study, the individual and combined effects of two
experimental exposures (ethanol and LPS) on the hepatic matrisome were
determined. The rationale for selecting LPS is that it induces a robust
inflammatory response in the liver. Exposure of the liver to low levels of LPS is
common and occurs through multiple means, including both acute and chronic
alcohol consumption (316). Whereas inflammatory responses triggered by small
doses of LPS are typically non-injurious, other stresses can synergistically
enhance the hepatotoxic response to LPS. Indeed, in addition to increasing
circulating LPS, ethanol also enhances inflammation and liver damage caused by
acute LPS exposure (71, 170). This ‘2-hit’ paradigm is a common factor in fatty
liver diseases (34). The results here demonstrate that the hepatic matrisome
responded dynamically to both stresses, not only increasing the net amount of
protein associated with the matrisome, but also differentially changed the
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amounts (Figure 5.5) and likely the composition (Figure 5.3) of the proteins
found.
This study was able to validate changes in the hepatic matrisome that
have been reported previously after LPS and/or ethanol exposure. Indeed, this
work validated that the fibrin(ogen) ECM is dramatically altered by LPS and
enhanced by the combination of LPS + ethanol. In the current study, LPS
exposure caused a nearly 14-fold increase in the fibrinogen gamma chain in the
GnHCl extract. Additionally, both LPS and ethanol caused fibrinogen chains to
appear in the NaCl and SDS extracts, suggesting an increased rate of turn-over
of this ECM component. The fibrin(ogen) gamma chain is a major component of
fibrin clots which form upon cleavage of the fibrinogen gamma chain, causing its
polymerization into insoluble fibrin fibers (317). Therefore, the localization of this
robust increase in fibrinogen gamma chain in the GnHCl fractions suggests that
there was an increase in fibrin(ogen) gamma chain polymerization into a lesssoluble and more highly cross-linked form. Furthermore, the combination of LPS
+ ethanol resulted in presence of the fibrin(ogen) gamma chain in the insoluble
pellet, which suggests additional modifications that increased insolubility (e.g.,
crosslinking). LPS also caused the appearance of serum amyloid A-1 and A-2
(SAA1 and SAA2) proteins, which are acute phase proteins whose production
and secretion by hepatocytes is increased by LPS (318, 319). In fact, LPS
administration resulted in the presence of or increased the levels of several other
acute phase proteins including haptoglobin, complement C, and ceruloplasmin,
all of which are known to be increased in liver by LPS administration (320-322).
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Proteomic analysis of liver tissue from animals exposed to chronic ethanol
exposure also validated changes that others have shown to be caused by
ethanol. Previous studies have shown that ethanol exposure enhances
fibronectin expression and deposition prior to the onset of fibrosis (28). In this
model of alcoholic steatohepatitis, we found that fibronectin expression was
increased by nearly 2-fold in the GnHCl extract compared to control livers.
Additionally, ethanol exposure increased the level of collagen 1α1, which has
previously been shown to be increased in patients (323) and in animal models of
alcoholic steatohepatitis (324). Recent studies have also implicated the highmobility group protein B1 as a contributor to ALD and have shown that
expression is increased in both the liver and serum after alcohol exposure (325).
In our study, HMGB1 was increased in the NaCl fraction by 2-fold.
Expression of several other matrix proteins were altered by chronic ethanol
exposure. For example, vitronectin levels were increased in the GnHCl extracts
of ethanol-treated liver. The extracellular glycoprotein vitronectin has previously
been linked to hepatic fibrosis. Indeed, end-stage hepatic fibrosis is
characterized by decreased circulating levels of vitronectin due to decrease in
hepatic function and an increase in vitronectin deposition locally in the liver (326,
327). The findings of this study suggest that more subtle changes in vitronectin
expression occur prior to the onset of fibrosis and hepatic decompensation.
Ethanol also resulted in the appearance of galectin-1. Galectin-1 is
glycosaminoglycan-binding lectin (328), which has been associated with cell
proliferation and adhesion through modulation of glycoprotein crosslinking.
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Galectin-1 may also play a role in hepatic inflammation and fibrinogenesis (329).
For example, galectin-1 has been shown to be protective against experimental
inflammatory liver injury (330). This role may be in contrast to later stages of
liver disease that correlate increased galectin-1 secretion from activated HSCs in
hepatic fibrosis (331, 332). Although additional studies will be required to
validate functional changes in these proteins after alcohol exposure, these data
suggest that ethanol is likely contributing to a myriad of changes in the
extracellular matrix composition, many of which have not yet been fully
investigated.
Changes in expression of protease and protease inhibitors can also
contribute to inflammatory liver injury and fibrogenesis. In the current study, a
number of matrix-associated proteases were present in the GnHCl extract of
ethanol-exposed liver including plasmin(ogen), antithrombin III, dipeptidyl
peptidase, and alpha-1-antitrypsin. Plasmin(ogen) is a well-known serine
protease which degrades fibrin into fibrin degradation products and is tightly
regulated by a series of activators (urokinase and tissue-type plasminogen
activators) and inhibitors (i.e. plasminogen-activator inhibitor 1; PAI-1). In this
study, both ethanol and LPS resulted in the presence of plasminogen in the
GnHCl extract, suggesting that plasmin(ogen) was tightly associated with the
ECM after either exposure. LPS also resulted in the presence of protease
inhibitors, such as serpine B5 (maspin) and PAI-1. Several other proteases and
protease inhibitors that may be critical for ECM homeostasis [e.g., transthyretin,
phosphatidylethanolamin-binding protein-1 (PEBP1), and serine protease
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inhibitor A2K] increased in response to ethanol and/or LPS. These data support
the notion that transitional remodeling of the hepatic matrisome is likely
bidirectional and driven by both increased secretion of matrix proteins as well as
changes in ECM degradation.
As mentioned above, ethanol is well-known to synergize liver damage caused
by LPS exposure. In the current study, we found that the combination of ethanol
and LPS resulted in unique changes to the hepatic matrisome compared to either
ethanol or LPS alone. Indeed, fibronectin and biglycan expression were all
differentially increase by co-exposure. Fibronectin accumulation caused by
ethanol may contribute to hepatic inflammation via stimulation of KCs (308).
Biglycan expression was also dramatically increased by the combination of
ethanol + LPS. Research suggests that biglycan may play a role in fibrotic liver
disease (315, 333). This small proteoglycan was first recognized as a structural
component and signaling molecule in the ECM due to its association with
collagen fibrils and its role in collagen fiber organization (334, 335). In addition to
its structural role, biglycan has been implicated in inflammation by retaining proinflammatory cytokines including TNFα and TGFβ (336) and activating TLR4
signaling (337); interestingly, in order to contribute to the inflammatory response,
biglycan must be released from the collagens of the ECM by one of several
MMPs (338). Areas with increased bigylcan expression have also been
associated with increased inflammatory cell migration (339). These data suggest
that biglycan expression may be increased in pre-fibrotic stages of liver disease.
In contrast, the combination of ethanol and LPS resulted in a synergistic
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decrease in the serine protease inhibitor phosphatidylethanolamine-binding
protein-1 (PEBP1). This enzyme has been shown to inhibit trypsin-like serine
proteases including thrombin, but not trypsin or tissue-type plasminogen activator
(296). Multiple studies have identified PEBP1 as a critical player in metastasis
(340), and have defined it as a metastasis suppressor gene (MSG) (341).
Additional studies which implicate a role for PEBP1 in inhibition of NFκB (342), a
well-recognized player in hepatic inflammation (343) further support a potential
role for PEBP1 in inflammatory liver injury. It is likely that other changes in the
ECM previously undetermined may also contribute to hepatic inflammation and
injury.
In summary, an extraction method to enrich the hepatic ECM was
developed and characterized. The results demonstrate that the hepatic
matrisome responds dynamically to both acute (LPS) and chronic (ethanol)
stresses, long before more dramatic fibrotic changes to the liver. It is likely that
these transitional changes to the hepatic ECM contribute, at least in part, to the
pathologic responses to these stresses. It is also interesting that several ECM
proteins responded similarly to both stresses, suggesting a common mechanism
in both models. Nevertheless, there were responses that were unique to the
individual and combined effects. These results therefore also serve as a
foundation for future analyses in hepatic models of liver disease.
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CHAPTER VI
DISCUSSION AND CONCLUSIONS
A. Restatement of goals and questions
The overall goal of the work described in this dissertation was to further
elucidate the role of ECM remodeling in liver injury and the potential role of such
changes on the pathology of other organs, such as the lung. The experiments in
Chapter III were performed to identify the potential role of gut dysbiosis in driving
fibrin accumulation and liver injury in a model of enhanced fatty liver disease
caused by the combination of HFD and arsenic. Chapter IV aimed to characterize
a model of concomitant liver and lung injury in the context of chronic alcohol
exposure that will allow further investigation of parallel and interdependent
mechanisms of injury in these two organs, including transitional tissue
remodeling. Finally, Chapter V of this dissertation describes a new method of
protein extraction which can be used for analysis of the extracellular matrix
proteome. Together, these studies shed new insight into the complex
mechanisms that mediate transitional tissue remodeling and injury in the liver
and lung.
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B. Major findings of this dissertation
1. Dysbiosis contributes to hepatic sensitization and transitional tissue
remodeling during NAFLD
Previous studies from this group have shown that coexposure to low
concentrations of arsenic and high-fat diet (HFD) enhanced liver injury and
inflammation (98); importantly, these effects of arsenic correlated with an
increase in proinflammatory fibrin ECM deposition. However, whether enhanced
hepatic injury in this model was due to interactions between arsenic and HFD
locally in the liver or distally in the gut was unclear. Therefore, the study
described in Chapter III was designed to identify changes in the gut microbiome
after concomitant HFD and arsenic exposure and to test the therapeutic potential
of the prebiotic oligofructose (OFC) in this model; a major endpoint was whether
or not this intervention would blunt the increase in fibrin ECM deposition caused
by the combination of arsenic and HFD.
Changes in the gut microbiome caused by HFD, as described in Chapter III
support the link between HFD and dysbiosis previously demonstrated by others
(78, 134). Additionally, this study found that arsenic alone impacted the gut
microbiome, leading to a net loss of commensal bacteria and expansion of the
population of Gram negative bacteria. Increases in Gram negative bacteria,
which harbor a lipopolysaccharide wall, can contribute to endotoxemia and have
been linked to liver injury (344, 345). Therefore, the increase in Gram negative
bacteria caused by arsenic may contribute to liver injury by enhancing HFDinduced endotoxemia. Another potential mechanism of enhanced injury may be
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‘upstream’ of arsenic exposure. For instance, HFD-induced steatosis and
endotoxemia may sensitize the liver to otherwise innocuous levels of arsenic.
HFD has previously been shown to sensitize the liver to injury by other factors,
including LPS (145, 146).
The work presented in Chapter III demonstrated a protective effect of OFC.
Protection conferred by OFC was evidenced by a reduction of liver steatosis,
fibrin ECM deposition and inflammation that is normally seen with HFD-feeding
and a prevention of expansion of Gram negative bacteria caused by arsenic
exposure, coupled with an expansion of potentially protective bacterial
populations. Protection against enhanced liver injury that was conferred by OFC
is likely mediated by both direct effects on the microbiome as well as potentially
indirect effects on hepatic sensitization. For example, protection against
increases in Gram negative bacteria, which can contribute to endotoxemia, may
confer protection against liver injury. Indeed, Adachi and colleagues
demonstrated that depletion of Gram negative bacteria by enteral antibiotic
administration protected against endotoxemia and liver injury caused by alcohol
exposure (344). Additionally, OFC has been shown to protect against HFDinduced endotoxemia (80). In agreement with this previous work, we found that
OFC protects against steatosis caused by HFD-feeding to animals. Steatosis
and endotoxemia are two factors known to sensitize the liver to injury (34, 35).
Therefore, protection against these changes by OFC feeding may diminish HFDinduced hepatic sensitization and, ultimately, protect against increased sensitivity
to arsenic toxicity.

128

It is hypothesized that the enhanced HFD-induced liver injury caused by
arsenic exposure is mediated at least in part via deposition of fibrin ECM. This
hypothesis is supported by previously established proinflammatory effects of
fibrin ECM in liver (29), as well as mechanisms hypothesized to be involved in
the atherogenic effects of arsenic in the vasculature (346). Here, this enhanced
fibrin accumulation caused by arsenic was almost completely blunted by OFC
administration. These data support a role for transitional matrix remodeling in the
setting of arsenic hepatotoxicity. Fibrin ECM accumulation in the liver can be
mediated via an increase in deposition (via activation of the coagulation
cascade), and/or via a decrease in degradation (i.e., fibrinolysis) caused by PAI-1
induction (29). In the work presented here, PAI-1 expression was significantly
increased by the combination of arsenic and HFD. The implications of potential
crosstalk between transitional tissue remodeling in the setting of fatty liver
disease is a focus of future work in this laboratory. The results of the current
study lend weight-of-evidence that transitional changes in the hepatic ECM play
a unifying role in the initiation and/or progression of fatty liver disease, be it from
alcohol or from diet (HFD).
2. Chronic ethanol exposure causes unique pro-inflammatory changes
in the liver and lung after systemic LPS administration
Chapter IV of this dissertation aimed to characterize a model of concomitant
liver and lung injury in the context of chronic ethanol exposure and to establish a
potential link between injury of these two organs. As mentioned in the
Introduction, work by this group and that of the Roman laboratory has been
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pursuing in parallel the role of transitional matrix changes in inflammatory liver
and lung injury. Whereas the detrimental effects of chronic alcohol exposure on
the liver and lung are well established separately, potential links between the two
are less well characterized. However, clinical studies have suggested a potential
interaction between the liver and lung; for example, hepatic cirrhosis increases
mortality due to acute lung injury to nearly 100% (152). Additionally, an
experimental model of endotoxic shock has shown that LPS-induced lung
damage required interaction with the liver (84). Therefore, the damage to liver
and lung caused by transitional ECM changes may not only be parallel
pathologic responses, but interdependent mechanisms. Elucidating these
mechanisms therefore offers the possibility to develop novel therapeutic
approaches. Prior to these critical experiments being performed, the model
needed to be developed.
In the work presented here, ethanol preexposure enhanced LPS-induced
injury and inflammation in both the liver and the lung. Interestingly, ethanol
preexposure caused changes to the mRNA expression of inflammatory cytokines
that was unique to each organ. For example, ethanol preexposure caused a
significant increase in TNFα mRNA expression in the liver which correlated with a
significant increase in plasma levels of TNFα in animals exposed to ethanol and
LPS. In contrast, ethanol preexposure did not alter TNFα expression in LPSexposed lungs. Ethanol preexposure did, however, enhance mRNA expression
of the TNFα sensitive genes MIP-2 and KC in the lung. Both MIP-2 and KC have
been shown to contribute to pulmonary injury caused by LPS (154, 178) and
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blocking TNFα expression has been shown to protect against increases MIP-2
and KC in the lung (88). To address the potential role of TNFα in driving
pulmonary MIP-2 levels, we used a TNFα binding antibody, etanercept, in an
attempt to block enhanced pulmonary injury caused by ethanol exposure. As
expected, etanercept blunted plasma TNFα levels. Etanercept also protected
against enhanced pulmonary mRNA expression of MIP-2 and KC in lung and
also caused a significant decrease in MIP-2 levels in the BALF. Attenuation of
the increase in MIP-2 correlated with protection against pulmonary injury, as
indicated by pulmonary pathology. These findings suggest that enhanced
systemic TNFα caused by ethanol preexposure may contribute to pulmonary
injury. Additionally, Kono and colleagues have suggested that KC-derived
inflammatory mediators, including TNFα, contribute to pulmonary injury after
systemic LPS exposure (347). Therefore future studies by our lab should aim to
elucidate the potential contribution of hepatic-derived TNFα using models that
specifically block the release of TNFα from the liver. This work also lays the
foundation to investigate the key role of ECM changes in both organs and their
independence in pathology.
3. The hepatic matrisome undergoes dynamic changes after ethanol
and LPS exposure.
The first 2 studies build on our understanding of the role of transitional ECM
changes in liver damage (Chapter III) and develop a new model to leverage
these questions in the interplay between liver and lung damage (Chapter IV);
however, a limitation of previous studies is that they generally investigated
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changes in one ECM protein at a time (e.g., fibrin; Chapter III) and ignore
structural changes that may occur with altered ECM protein turnover. Although
the role of the ECM is well established in the setting of chronic liver injury and
alcoholic liver disease (ALD), the study of the hepatic ECM changes has been
focused primarily on dramatic changes in the ECM during fibrogenesis and
specifically the contribution of collagen ECM in driving this process. However,
recent studies have shown that multiple ECM proteins contribute to fibrogenesis
(48), and that the hepatic ECM is altered prior to fibrogenesis (28). Therefore the
goal of Chapter V was to adapt a sequential protein extraction method developed
for cardiovascular research (95-97) to facilitate LC-MS analysis of global
changes in the hepatic matrisome after chronic alcohol exposure. Such an
approach could discover new proteins that are changed by insults. Furthermore,
the sequential extraction methods yield new insight into potential changes in
turnover.
The 3-step protein extraction described in Chapter V allowed efficient
extraction of the hepatic ECM proteome into four distinct extracts. These
consisted of loosely-associated ECM proteins (NaCl extract), intracellular and
membrane-associated proteins (SDS extract), tightly bound ECM proteins
(GnHCl extract), and highly insoluble ECM components (the remaining pellet). A
total of 147 extracellular proteins were identified in this study (Table 5.1).
Qualitative analysis of the ECM proteins in each fraction demonstrated that both
ethanol and LPS caused dynamic changes in the ECM. While neither ethanol
nor LPS changed the general pattern of proteins found in the various extracts,
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both tended to increase the number of ECM proteins. Despite no changes in the
general pattern of proteins, there were 22 proteins and 14 proteins whose
presence was unique to ethanol and LPS exposure, respectively. These unique
subsets of proteins may play critical roles in the hepatic response to stress.
There were also quantitative changes in protein abundance caused by ethanol or
LPS that may impact function. Interestingly, the combination of ethanol and LPS
caused both qualitative and quantitative changes in the hepatic ECM. Analysis
of these global changes in the hepatic matrisome may identify new key players in
the development of liver injury, the roles of which can be validated in future
studies. Furthermore, analysis of changes specific to chronic ethanol exposure
may reveal new insights into the mechanisms of liver sensitization caused by
alcohol, thus leading to potential therapeutic targets. Most importantly, this work
emphasizes dynamism in the hepatic ECM proteome responses to stress that
opens a new critical area of future research. This work also lays the foundation
for future studies, such as investigating the interactive changes between the
hepatic and pulmonary ECM proteome, using the model established in Chapter
IV.

C. Significance of new findings
The findings of Chapter III have identified dysbiosis as a potential
mechanisms by which HFD feeding may predispose individuals to increased
toxicity from environmental toxicant, such as arsenic. While the levels of arsenic
exposure to most Americans is typically considered sub-toxic, data presented
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here suggest that other factors which alter the gut microbiome, like HFD, may
sensitize the liver to injury by otherwise innocuous exposures. Such interactions
are becoming more relevant as the incidence of NAFLD continues to increase
both nationally as well as globally. Indeed, the estimated prevalence of NAFLD
in the US may be as high as 19% (39), however only a minority of these
individuals will progress to later stages of disease (40-42). A better
understanding of the interactions that occur between diet and environmental
exposures will offer new insights into potential risk factors for the development of
NAFLD in the human population and allow better identification of at-risk
populations.
The role of inter-organ crosstalk during disease states such as multi-organ
failure and sepsis is well established but mechanisms underlying these
interactions can be very complex and largely remain incompletely understood.
Chapter IV characterized a model of concomitant liver and lung injury in the
setting of chronic alcohol exposure. Characterization of this model will bring
attention to the parallel mechanisms of injury in these two organs as well as the
potential for extensive interdependence between them. Better understanding of
the contribution of hepatic-derived mediators in the increased susceptibility to
lung injury after alcohol exposure may provide new insights into the mechanisms
underlying dysregulated immune response and tissue remodeling in the lung.
Chapter V describes a new method of hepatic matrisome extraction and
analysis. Implementation of this new method will allow identification of new
players in fatty liver disease paradigm. Furthermore, adaptation of this method
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will allow analysis of global changes in the extracellular matrix in other models of
liver injury (i.e., NAFLD) and in other organs (i.e., the lung). Identifying new
targets in disease progression could potentially be beneficial for individuals with
early stages of liver disease by offering a means to prevent progression to later
stages of disease.

D. Strengths and Weaknesses
1. Strengths
There are several strengths of this dissertation. One such strength is that
it identifies gut dysbiosis as a new potential mechanism mediating interaction
between diet-induced liver disease and environmental toxicants (i.e., arsenic
exposure). The findings of this study provide additional support for the use of
prebiotics as a potential therapeutic for early stages of liver disease, and
potentially as a prophylactic therapy to protect against environmental liver
disease. This work also describes an initial characterization of a new model of
concomitant liver and lung injury after chronic alcohol exposure.
Characterization of this new model will allow a better understanding of how
alcohol affects the entire person (or mouse) rather than an individual organ. Use
of this model may also provide new insights into why some lung-specific
approaches to the study and treatment of pulmonary injury after alcohol exposure
are not completely effective and that systemic therapies (e.g., etanercept) may
confer new avenues of treatment.
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Additionally, a new method of protein extraction has been validated for
use with liver tissue, effectively allowing the analysis of low-expressing and
highly insoluble hepatic ECM proteins. LC-MS analysis of these extracts has
opened the door for a discovery-based research approach that can help to
expand the foundation of new hypothesis-driven studies and possibly increase
the identification of new therapeutic targets. Importantly, this work also
demonstrates that the hepatic ECM proteome responds dynamically to stress.
Whereas such dynamism for the ECM is well understood in other organs and
systems, most work in the liver has focused predominantly on hepatic fibrosis.
Another strength of this work is the use of whole animal models. Most of
the experiments described here were performed in vivo. As mentioned
previously, liver disease and the effects of alcohol use are complex phenomena
which are not limited to a single organ or cell type. The use of in vivo models in
the experiments described here allowed the study of interactions between
multiple organs, including the gut, liver, and lung. Indeed, all of the questions
that were addressed here likely could not be sufficiently recapitulated in a simpler
model system (e.g., cultured cells).

2. Weaknesses
Although the use of animal models of disease is a strength, it is also a
potential source of complexity. There is almost always an inverse relationship
between the validity of the model and the degree to which the model can be
controlled and therefore how certain our conclusions may be. Therefore,
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although in vivo is a more valid approach than simpler models, the ‘black box’ is
also much larger. Furthermore, although in vivo research is preferred for the
study of inter-organ phenomena, no animal model can completely recapitulate
the human condition. Indeed, there is currently no rodent model that exactly
represents the progression of fatty liver disease, increased susceptibility to lung
injury, or the typical human microbiome. It is therefore possible that the
observed changes in the microbiome or mastrisome are unique to the species
tested and have little direct relevance to human beings.
The work presented here identified the microbiome as a site for interaction
between a HFD and the environmental contaminant arsenic. This study focused
on changes in the microbiome caused by arsenic, HFD and OFC administration
rather than the potential effects that the microbiome might be having on these
parameters. Lu et al have shown that arsenic-induced dysbiosis does cause
functional changes in the gut metabolome (2). Future studies will be necessary
to pare out additional, bidirectional changes in the microbiome and arsenic
metabolism.
One weakness of this project is the use of systemic administration of
etanercept to block TNFα investigate the potential interaction between liver and
lung injury. Whereas the liver is known to contribute to enhanced systemic levels
of pro-inflammatory cytokines, including TNFα, systemic etanercept binds TNFα,
regardless of source. Studies that aim to identify the role of hepatic-derived
mediators in the development of lung injury will require an experimental model
which allows specific blockage of liver-derived TNFα.
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The experiments described in Chapter V identified changes in the hepatic
matrisome after alcohol and LPS exposure. Unfortunately, due to the cost of LCMS analysis, study samples were pooled prior to LC-MS. This is a significant
weakness of this study as qualitative changes in protein expression could have
been driven by a single sample. Future studies would be strengthened by
analysis of individual samples as separate runs, or via ‘multiplexing’ the samples
with protein tagging. Additionally, the experiments described herein did not
determine the functional significance of the changes in the ECM. Future studies
will be required to validate that changes in the matrisome caused by LPS and/or
ethanol cause functional change in vivo and in vitro.

E. Future Directions
While the experiments described in this dissertation answered specific gaps
in our knowledge of ECM remodeling, it has also created new questions that will
need to be addressed in future studies. Some of these are discussed below.
1. Does HFD-induced dysbiosis change arsenic metabolism and/or
absorption?
Because the experiments described in Chapter III were largely concerned
with the effect of arsenic, HFD, and OFC on the gut microbiome, the bidirectional
effects of dysbiosis on arsenic metabolism and absorption were not determined.
Lu and colleagues have previously shown that higher levels of arsenic can cause
changes in the gut metabolome (124) and that dysbiosis caused by bacterial
infection altered arsenic metabolism (348). In vitro studies have also shown that
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the bacteria of both the mouse and human gut can metabolize arsenic in vitro
(141-143) . Such findings suggest that dysbiosis caused by HFD could cause
dramatic changes in arsenic metabolism. An important endpoint of future studies
would include hepatic levels of arsenic and arsenic metabolites. Indeed,
increased levels of arsenic in the liver of HFD-fed mice may contribute to
enhanced liver injury in the model presented here. On a related note, it would be
interesting to determine if arsenic has global effects on the hepatic matrisome;
this question is especially valid, since previous work by others has shown that
very low concentrations of arsenic cause hepatic endothelial remodeling (46)
Work by others in our group are pursuing these questions using the ECM
proteomic approach developed in Chapter V.

2. Does liver-derived TNFα contribute to the alcoholic lung phenotype?
In the experiments described in Chapter IV, etanercept was used to identify
the potential role of extra-pulmonary TNFα in driving lung inflammation. While
studies have shown that hepatic Kupffer cells are responsible for ~90% of the
increase in plasma TNFα caused by LPS (172) the role of liver-derived TNFα
needs to be determined using a model in which one can specifically block TNFα
release from the liver. One approach to this problem would be to use Kupffer cell
chimeric mice to impair production of tumor necrosis factor α converting enzyme
(TACE) in Kupffer cells. TACE is an enzyme required for cleavage and systemic
release of TNFα into the blood. The use of such chimeras would target TACE
deficiency to the Kupffer cells and thereby block hepatic TNFα signaling. These

139

studies would identify the contribution of hepatic TNFα in the lung alterations
caused by chronic alcohol exposure. The protocol for generating the chimeras to
perform these studies are currently being optimized.

3. What are the functional effects of changes in the hepatic matrisome
of LPS and ethanol-exposed livers?
The method described in Chapter V identified dynamic changes in the hepatic
matrisome after ethanol and/or LPS exposure. However, the functional effects of
these changes has yet to be determined. Others have shown that the
extracellular matrix from decellularized tissues can be solubilized and used to
coat cell culture plates where it serves as a substratum for cells in vitro (349). By
using plates coated with the ECM of animals exposed to ethanol or LPS, the
functional effects of changes in the ECM composition on cell migration activation
could be determined. In vivo experiments using inhibitors that block the
interactions between the ECM and cell surface receptors may also provide
insight into the functional effects of changes in the hepatic matrisome after
alcohol and LPS exposure. Indeed, previous studies from our group have shown
that the integrin inhibitor CycloRGDfV can protect against enhanced liver injury
and inflammation caused by acute ethanol exposure and LPS (350).

4. What changes does alcohol exposure cause to the lung matrisome?
Experimental alcohol exposure has been shown to contribute to the alcoholic
lung phenotype which is characterized by oxidative stress (58), dysregulated
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immune response (186, 189), and tissue remodeling of the lung (59, 351, 352).
Indeed, studies have shown that alcohol exposure increases the expression of
fibronectin by pulmonary fibroblasts (68). Additional studies have shown that
ethanol also causes increased expression and activity of matrix
metalloproteinases (MMPs) (62). Furthermore, the fibronectin-rich matrix
produced by alcohol-exposed alveolar macrophages appears to contribute to
functional changes in the lung after alcohol exposure, including monocyte
activation (353). A discovery-based method, such as that described in Chapter
V, would allow for analysis of global changes to the pulmonary matrisome after
alcohol exposure. Furthermore, identification of new players in transitional
tissue remodeling in the lung would expand the foundation for new hypothesisdriven studies investigating the role of ECM proteins in alcohol-related
susceptibility to acute lung injury.

Summary and Conclusions
The overall goal of the work described in this dissertation was to build upon the
unifying hypothesis that changes in the ECM contributes to hepatic pathology as
well as pathology in other organs, such as the lung. The experiments described
in Chapter III further support the critical role of fibrin deposition in the
development of steatohepatitis and the potential contribution of arsenic exposure
on hepatic tissue remodeling. These findings suggest that future studies by our
group should include investigation of changes in the hepatic extracellular matrix
in models of non-alcoholic liver disease. Chapter IV characterized a new model
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of concomitant liver and lung injury in the context of chronic alcohol exposure
that will lay the foundation for testing the hypothesis that liver injury is critical to
transitional ECM remodeling in the lung. Finally, Chapter V described a new
proteomic strategy for characterizing the extracellular proteome which will allow
identification of new players in transitional tissue remodeling in the liver and
potentially the lung in future experiments. Taken together, this work has shed
new insight into the complex interplay between tissue injury and matrix
dyshomeostasis.
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ABBREVIATIONS

ADAMTs disintegrin and metalloproteinase with thrombospondin motif
ADH

Alcohol dehydrogenase

ALD

Alcoholic liver disease

ALI

Acute lung injury

AMPB

Alpha-1-microglobulin/bikunin precursor

ALT

Alanine aminotransferase

ARDS

Acute respiratory distress syndrome

As

Arsenic

ASH

Alcoholic steatohepatitis

AST

Aspartate aminotransferase

BAL(F)

Bronchioalveolar lavage (fluid)

BSA

Bovine serum albumin

BW

Body weight

CAE

Chloroacetate esterase

CID

Collision induced dissociation

CRELD2

Cysteine-rich with EGF-like domain protein 2

CYP2E1

Cytochrome P450 2E1

ECM

Extracellular matrix

Etan

Etanercept

ETD

Electron transfer dissociation

EtOH

Ethanol

FA

Formic acid

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase
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GI

Gastrointestinal

GnHCl

Guanidine Hydrochloride

GO

Gene ontology

H&E

Hematoxylin & eosin

HFD

High fat diet

HMGB1

High mobility group protein B1

HSCs

Hepatic stellate cells

i.p.

intraperitoneal

IL-10

Interlukin-10

IL-1b

Interleukin-1β

IL-2

Interleukin-2

IL-6

Interleukin-6

IL-8

Interleukin-8

KC

Keratinocyte chemoattractant

LC

Liquid chromatography

LefSe

Linear effect size

LFD

Low fat diet

LPS

Lipopolysaccharide

LW

Liver weight

MD

Maltose-dextrin

MIP-2

Macrophage inflammatory protein

MMPs

Matrix metalloproteinases

MS

Mass spectroscopy

NaCl

Sodium chloride

NAFLD

Non-alcoholic fatty liver disease

NASH

Non-alcoholic steatohepatitis

NEFA

Non-esterified fatty acid

OFC

Oligofructose

OTU

Operational taxonomic unit
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PAI-1

Plasminogen activator inhibitor

PCoA

Principle coordinate analysis

PEBP1

Phosphatidylethanolamine-binding protein

RANTES

Regulated on activation, normal T cell expressed and secreted

SAA1

Serum amyloid A1

SAA2

Serum amyloid A2

SDS

Sodium dodecyl sulfate

TG

Triglycerides

TGFβ

Transforming growth factor beta

TIMP

Tissue inhibitor of matrix metalloproteinases

TNFα

Tumor necrosis factor-alpha
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liver injury caused by arsenic in a model of NASH. Ohio Valley Society of
Toxicology, University of Louisville, Louisville, KY
3. Research Seminar, 11/12, Parallel and interdependent mechanism of
alcohol-induced organ injury in the liver and lung. University of Louisville
Alcohol Research Center, Louisville, KY
4. Research Seminar, 8/11 OVSOT Summer Meeting. CycloRGDfV protects
against LPS-induced liver injury caused by ethanol in mice.
5. Research Seminar, 03/11, Integrin inhibitor Cyclo-RGDfV blunts enhanced
LPS-induced liver injury caused by ethanol in mice. University of Louisville,
Seminar in Pharmacology and Toxicology, Louisville, KY.
POSTERS
National
1. Poster Presentation 09/14, The prebiotic oligofructose protects against
enhanced liver injury caused by arsenic in a model of NASH, Tamburro
Symposium on Environmental Chemicals and Liver Disease, Louisville, KY
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2. Poster Presentation 3/14 The prebiotic oligofructose protects against
enhanced liver injury caused by arsenic in a model of NASH, Society of
Toxicology, Phoenix, AZ
3. Poster Presentation 11/13, The prebiotic oligofructose protects against
enhanced liver injury caused by arsenic in a model of NASH, American
Association for the Study of Liver Disease, Washington D.C.
4. Poster Presentation, 11/11, Integrin inhibitor Cyclo-RGDfV blunts
enhanced LPS-induced liver injury caused by ethanol in mice. American
Association for the Study of Liver Disease, San Francisco, CA.
Local/Regional
1. Poster Presentation 09/14, Characterization of the liver:lung axis in alcoholinduced lung damage, Research!Louisville, Louisville, KY
2. Poster Presentation 09/13, The prebiotic oligofructose protects against
enhanced liver injury caused by arsenic in a model of NASH,
Research!Louisville, Louisville, KY
3. Poster Presentation, 10/12, Integrin β3-/- mice are protected against
enhanced alcohol-induced liver injury. Research!Louisville Louisville, KY
4. Poster Presentation, 10/11, Integrin αvβ3 mediates ethanol-enhanced liver
damage caused by LPS. Research!Louisville, Louisville, KY.
5. Poster Presentation, 10/11, Ethanol sensitization to LPS-induced liver
injury: protection by the integrin inhibitor, cycloRGDfV. Ohio Valley Society
of Toxicology Regional Meeting, Dayton, OH.
ABSTRACTS
National
1. Massey VL, Poole LG, Torres E, Dolin C, Merchant ML, Ritzenthaler J,
Roman J, Arteel GE. (2014) Characterization of the liver:lung axis in
alcohol-induced lung damage. Hepatology 59 (S1) 616
2. Anders LC, Douglas AN, Mohammad MK, Massey VL, Kirpich IA, Falkner
KC, Warner NL, Arteel GE, Cave M, McClain CJ and Beier JI (2014) Vinyl
Chloride Predisposes The Liver To Injury: Implications For Human
Exposure. Gastroenterology 146(5):S910. (Selected for oral presentation).
3. Massey VL, Schmidt RH, Tan M, Watson WH, Arteel GE. (2014) The
prebiotic oligofructose protects against enhanced liver injury caused by
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arsenic in a model of NASH The Toxicologist. Supplement to Toxicological
Sciences 138(1) 1323
4. Anders L, Douglas A, Guardiola J, Massey VL, Kirpich I, Mohammad M,
Falkner KC, Cave M, McClain C, Beier J. (2014) An environmental 2nd hit:
effect of vinyl chloride exposure on liver injury in experimental
hepatotoxicity and in humans. The Toxicologist. Supplement to
Toxicological Sciences. 138(1) 1879
5. Massey VL, Schmidt RH, Tan M, Watson W, Arteel GE (2013) The
prebiotic oligofructose protects against enhanced liver injury caused by
arsenic in a model of NASH. Hepatology 58 (S1) 739A
6. Schmidt RH, Massey VL, Jokinen J, Falkner KC, Beier JI, Arteel GE
(2013) Olanzapine-induced liver injury: direct metabolic effects on liver and
exacerbation by high-fat diet. Hepatology 58 (S1) 704A
7. Schmidt RH, Tan M, Jokinen J, Massey VL, Zhong H, Arteel GE (2012)
Arsenic enhances experimental liver disease via altering GI tract function:
protection with prebiotics. Hepatology 56 (S1): 89A
8. Massey VL, Beier JI, Schmidt RH, Zhong H, Arteel GE (2011) Integrin
inhibitor Cyclo-RGDfV blunts enhanced LPS-induced liver injury caused by
ethanol in mice. Hepatology 54(S1):970A
9. Tan M, Massey VL, Ding X, Zhong H, States JC, and Arteel GE (2010)
Arsenic pre-exposure delays cell cycle entry and progression in mouse
liver after partial hepatectomy. Hepatology 52:462A
Local/Regional
1. Massey VL, Poole LG, Torres E, Dolin C, Merchant ML, Ritzenthaler J,
Roman J, Arteel GE. (2014) Characterization of the liver:lung axis in
alcohol-induced lung damage. Research!Louisville. Louisville, KY.
2. Christine DE, Massey, VL, Poole, LG, Siow, DL,Merchant, ML, Wilkey,
DW, Arteel,GE. (2014) The hepatic ‘matrisome’ responds dynamically to
stress: novel characterization of the ECM proteome. Research!Louisville.
Louisville, KY.
3. Watson W, Burke T, Massey VL, Arteel GE, Merchant ML (2014) Activity
of the zinc finger transcription factor HNF-4a is inhibited by arsenic in the
livers of mice with diet induced non-alcoholic fatty liver disease.
Research!Louisville. Louisville, KY.
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4. Poole LG, Massey VL, Dolin C, Merchant M, Beier JI, Roman J, Arteel GE
(2014) Ethanol-induced changes in the hepatic ECM directly enhance the
pro-inflammatory response of macrophages. Research!Louisville.
Louisville, KY.
5. Bushau, A, Anders L, Douglas A, Poole LG, Massey VL, Lang A, Falkner
C, Cave M, McClain C, Beier J (2014) Mechanistic insights into vinyl
chloride-induced liver injury. Research!Louisville. Louisville, KY.
6. Massey VL, Schmidt RH, Tan M, Watson WH, Arteel GE (2013) The
prebiotic oligofructose protects against enhanced liver injury caused by
arsenic in a model of NASH. Ohio Valley Society of Toxicology Annual
Meeting, Louisville KY
7. Massey VL, Schmidt RH, Tan M, Watson WH, Arteel GE (2013) The
prebiotic oligofructose protects against enhanced liver injury caused by
arsenic in a model of NASH. Research!Louisville
8. Poole LG, Jokinen JD, Massey VL, Beier JI, and Arteel GE (2013)
Sinusoidal endothelial cell-derived extracellular matrix regulates basal and
stimulated macrophage activation. Research!Louisville.
9. Massey VL, Poole LG, Schmidt RH, Arteel GE (2012) Integrin β3-/- mice
are protected against enhanced alcohol-induced liver injury.
Research!Louisville Louisville, KY
10. Massey VL, Beier JI, Schmidt RH, Zhong H, Arteel GE (2011) Ethanol
sensitization to LPS-induced liver injury: protection by the integrin inhibitor,
cycloRGDfV. Ohio Valley Society of Toxicology Annual Meeting, Dayton,
Ohio
11. Massey VL, Beier JI, Schmidt RH, Zhong H, Arteel GE (2011) Integrin
αvβ3 mediates ethanol-enhanced liver damage caused by LPS.
Research!Louisville Louisville, KY
PUBLICATIONS
Papers
1. Massey VL, Dolin C, Poole LG, Wilkey D, Merchant ML, Torres E, Roman
J, Arteel GE. The hepatic ‘matrisome’ responds dynamically to stress:
novel characterization of the ECM proteome (in preparation)
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2. Massey VL, Torres E, Poole LG, Schmidt RH, Ritzenthaler J, Roman J,
Arteel GE Characterization of a model of concomitant liver and lung injury
in a 2-hit model of chronic alcohol exposure (in preparation)
3. Massey VL, Schmidt RH, Tan M, Stocke K, Neal RE, Barve S, Arteel GE.
The prebiotic oligofructose protects against arsenic-enhanced liver injury
in a model of NAFLD via modulation of the gut microbiome (in preparation)
4. Schmidt RH, Jokinen JD, Massey VL, Falkner KC, Shi X, Yin X, Zhang X,
Beier JI, Arteel GE (2013) Olanzapine activates hepatic mammalian target
of rapamycin (mTOR): New mechanistic insight into metabolic
dysregulation with atypical antipsychotic drugs. J Pharmacol Exp Ther
5. Massey VL and Arteel GE (2012). Acute alcohol-induced liver injury.
Frontiers in Physiology. 3 (193) 1-8
Book Chapters
1. Arteel GA, Massey VL, Ritzenthaler JD, Roman JR. The Gut/Liver/Lung
axis and alcohol-induced-tissue pathology.

185

